 
 
A Randomized, Phase II, Multi center, Open Label  Study Evaluating  
Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, 
Ann Arbor 1/2 Confirmed Acute Graft -Versus -Host Disease  
 
BMT CTN PROTOCOL 1 501 
Version 2.0 
 
Study Chairpersons  
Joseph Pidala, MD, PhD1and Margaret MacMillan, MD3 
 
Protocol Team  
Amin Alousi, MD2 
Claudio Anasetti, MD1 
Joseph Antin, MD4 
Peter Dawson, PhD5 
Adam Mendizabal, PhD5 
James Ferrara, MD6 
Vincent Ho, MD4 
Mary Horowitz, MD7 
John Levine, MD8 
Madan Jagasia, MD10 Eric Leifer, PhD9 
Marco Mielcarek, MD11 
Brent Logan, PhD7 
Shernan Holtan, MD3 
Javier Bolaños -Meade, MD12 
Mehdi Hamadani, MD7 
Alan Howard, PhD13 
Theresa  Pritchard , MS5 
 
Lauren Kunz, PhD9 
 
Sponsored by the National Institutes of Health  
National Heart, Lung, and Blood Institute  
National Cancer Institute  
 
1 H. Lee Moffitt Cancer Center  
2 University of Texas, MD Anderson Cancer 
Center  
3 University of Minnesota 
4 Dana Farber Cancer Institute  
5 The E mmes  Corporation  
6 Mount Sinai  Medical Center  
7 Center for International Blood and Marrow 
Transplant Research, Medical College of 
Wisconsin  8 University of Michigan  
9 National Heart, Lung, and Blood Institute  
10 Vanderbilt University Medical Center   
11 Fred Hutchinson Cancer Research Center  
12 Johns Hopkins University  
13 National Marrow Donor Program  
 
 
 
_______________________________  _______________________________  
Approval Signature (Protocol Chair)  Approval Signature (Protocol Officer)  

 
Core Study Participants:   Affiliate Study Participants:  
BMT Program at Northside Hospital  
Baylor Colleg e of Medicine Consortium  
Case Western Reserve University Consortium  
City of Hope National  
Dana Farber Consort ium 
Duke University Medical Center  
Fred Hutchinson Cancer Research Center  
H. Lee Moffitt Cancer Center  
Johns Hopkins University  
Memorial Sloan -Kettering Cancer Center  
Ohio  State Consortium  
Pediatric BMT Consortium  
University of Florida Consortium  
University of Michigan Consortium  
University of Minnesota  
University of Nebraska Consortium  
University of Pennsylvania Cancer Center  
University of Texas, MD Anderson Cancer Center  
Virginia Commonwealth University MCV Hospitals  
Washington University, Barnes Jewish Hospital  
  Medical College of Wisconsin  
 
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
iii PROTOCOL SYNOPSIS – BMT CTN PROTOCOL 1501  
 
A Randomized, Phase II, Multi center, Open Label Study Evaluating  Sirolimus and 
Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed 
Acute Graft -Versus -Host Disease  
 
 
Co-Chairs:  Joseph Pidala, MD , PhD and Margaret MacMillan, MD  
 
Study Design:  The study is a Phase II  randomized, open label, multicenter trial 
designed to identify whether sirolimus is a potential alternative to 
prednisone as an up -front treatment for patients with  standard -risk 
acute GVHD defined according to clinical and biomarker -based 
risk stratific ation .  
  
Patient s with previously untreated, standard -risk acute GVHD, 
according to the refined Minnesota Criteria , who are in need of 
systemic therapy,  will have a 5 mL blood sample collected prior to 
randomization  to assess their biomarker Ann Arbor Risk status .  
Ann Arbor scoring results will be provided 48 -72 hours after 
randomization. Patients will begin their study  treatment  
assignment s within 24 hours of randomization. Those  with 
biomarker results of combined AA1/2 risk will continue on their 
randomized study treatment and will be included for primary 
endpoint analysis and all planned study procedures and 
assessments. In contrast, patients with AA3  biomarker  risk and 
those patients with missing biomarker result s may continue on 
their randomized therap ies or start another therapy  at their 
physicians ’ discretion s.  In addition, AA3 risk patients and those 
with missing results will not be considered in primary endpoint 
analysis, but will be included in a subset ana lysis.  
 
Primary Objective:  The primary objective is to assess the rate of complete remission 
(CR)/partial remission (PR) on day 28 post -randomization  in 
patient s with standard -risk acute GVHD defined by both clinical 
and AA1/2 risk status.  
 
Secondary Objec tives:  Secondary objectives are to assess the following:  
1. The proportion of patients with an acute GVHD response on 
Day 28 (CR or PR) and who are on a prednisone (or prednisone 
dose-equivalent corticosteroid) dose of 0.25mg/kg/day or less.  
2. Proportions of CR, PR, mixed response, no response and 
progression among surviving patients at Day 14, 28 and 56.  
3. Treatment failure (treatment failure defined as: no response, 
progression, administration of additional therapy for GVHD 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
iv beyond primary thera py, or mortality) at Day 14, 28, and 
56.Incidence of chronic GVHD by 6 and 12 months post -
randomization.  
4. Incidence of systemic infections within 6 months of 
randomization.  
5. Freedom from acute GVHD progression, chronic GVHD, 
malignancy relapse and mortality at 6 months and 12 months 
post-randomization.  
6. Disease -free and overall survival at 6 and 12 months post 
randomization.  
7. GVHD -free survival at 6 and 12 months post -randomization.   
8. Non-relapse mortality at 6 and 12 months post -randomization.  
 
Explorato ry Obj ectives:  Explorato ry objectives are to assess the following:  
1. Steroid -dose (measured in prednisone -equivalent) on Days 7, 
14, 21, 28, 35, 42 and 56.  
2. Use of topical (skin, GI) agents for acute GVHD therapy.  
3. Incidence of discontinuation of immune suppression,  and 
immune suppression discontinuation without GVHD or disease 
progression/recurrence by Days 56, 180, and 36 5 post-therapy.  
4. Incidence of EBV -associated lymphoproliferative disorder or 
EBV reactivation requiring therapy  
5. Incidence of corticosteroid - and si rolimus -associated 
complications (collected in all patients):  
a. Incidence of hyperglycemia (defined as a random 
glucose >200mg/dL or fasting glucose >126mg/dL)  and 
use of diabetes therapy (use of insulin and/or oral 
medications to control and/or maintain glu cose levels)  
at baseline, Day 28 and Day 56 . 
b. Change from baseline in functional myopathy score at 
Day 56 and 6 -months post -randomization.  
i. Hip Flexor and Quadriceps Strength via 
handheld dynamometer  
ii. Two Minute Walk Test  
iii. 5-time Sit -to-Stand  
iv. Adult Myopathy A ssessment Tool (AMAT)  
c. Incidence of hyperlipidemia as measured by fasting 
lipid panel at baseline, Days 28, 56 and 180 post -
randomization.  
d. Incidence of post -transplant thrombotic 
microangiopathy (TMA) by 6 months post -
randomization.  
6. Proportion of patients requiring therapy for CMV -reactivation 
by day 56 post -randomization.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
v 7. Change in patient -reported outcomes from enrollment to Day 
56, 6 months and 12 months . 
a. MD Anderson Symptom Inventory (MDASI)  
b. FACT -BMT  
c. MOS Short Form 36 (SF -36)  
d. PedsQL (Pediatric patients ) 
8. A secondary descriptive analysis will evaluate outcomes for 
AA3 patients.  
 
 
Eligibility:  Patients of all ages with newly diagnosed standard -risk acute 
GVHD, diagnosed according to Refined Minnesota Criteria . All 
allogeneic donor sources and all conditioning regimens are 
allowed. Biopsy confirmation of GVHD is not required unless 
institutional practice mandates biopsy confirmation to make a 
GVHD treatment decision. Patients must have an absolute 
neutrophil coun t (ANC) greater than 500/µL.  Patients must be 
able to to lerate oral or enterically -administered medication. 
Patient s must have 5 mL blood sample s collected for Ann Arbor 
Scoring. No previous systemic immune suppressive therapy for 
acute GVHD is allowed ex cept topical corticosteroid use.  Patients 
receiving sirolimus within 14 days of screening will be excluded.  
Patients with an active or recent (within 7 days) episode of 
transplant associated microangiopathy are not eligible.  Patients 
with acute GVHD aft er donor lymphocyte infusion are not eligible.  
Patients with clinical presentation resembling de novo chronic 
GVHD or overlap syndrome are not eligible.  
 
Treatment Description:  Patients will be randomly assigned 1:1 to sirolimus vs. prednisone 
at 2mg/kg/da y starting dose. Sirolimus will be loaded and then 
kept at maintenance dosing for target therapeutic levels for 
minimum duration through Day 56 post -randomization  Prednisone 
will be kept at 2mg/kg/day x 3 days, and then tapered according to 
individual tre ating clinician judgment.  
 
Accrual Objective:  150 total patients will be enrolled and randomized 1:1 to sirolimus 
vs. prednisone.  It is anticipated that ~20% of randomized patients 
will have AA3 status or missing biomarker results resulting in 120 
patients  for the analysis of the primary endpoint.  
 
Accrual Period:  The estimated accrual period is 2 years.  
 
Study  Duration:  Patients will be followed for 12 months following initiation  of 
therapy.  
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
vi Safety Monitoring:  The rate of failure of sirolimus therapy by Day 42 post-
randomization, defined as the addition of a systemic immune 
suppressive therapy beyond prednisone among those patients 
originally treated with sirolimus, will be monitored using a 
sequential probability ratio test (SPRT) for binary  data.  The SPRT 
will contrast a 25% and 50% 42-day rate of sirolimus failure . Day 
56 mortality will also be assessed for safety monitoring  using a 
censored exponential SPRT contrasting a 10% and 25% rate of 
overall mortality . 
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
vii  TABLE OF CONTENTS  
 
1. BACKGROUND AND RATIONALE  ................................ ................................ .........  1-1 
1.1. Introduction  ................................ ................................ ................................ ....................  1-1 
1.2. Risk Stratification by Onset Organ Severity  ................................ ...............................  1-2 
1.3. Risk Stratification by Blood Biomarkers  ................................ ................................ ..... 1-2 
1.4. Results of Previous aGVHD Therapy Trials  ................................ ...............................  1-3 
1.5. Sirolimus as Primary, Steroid -Free aGVHD Therapy  ................................ ...............  1-4 
1.6. Study Rationale:  ................................ ................................ ................................ .............  1-5 
2. STU DY DESIGN  ................................ ................................ ................................ ............  2-1 
2.1. Study Overview  ................................ ................................ ................................ ..............  2-1 
2.2. Hypothesis and Specific Objectives  ................................ ................................ ..............  2-1 
2.2.1.  Primary Hypothesis  ................................ ................................ ................................ ..... 2-1 
2.3. Study Objectives ................................ ................................ ................................ .............  2-1 
2.3.1.  Primary Objective:  ................................ ................................ ................................ ...... 2-1 
2.3.2.  Secondary Objectives are to assess the following:  ................................ .....................  2-1 
2.3.3.  Exploratory Objectives are to assess the following:  ................................ ...................  2-2 
2.4. Patient Eligibility  ................................ ................................ ................................ ...........  2-2 
2.4.1. Inclusion Criteria  ................................ ................................ ................................ .........  2-2 
2.4.2.  Exclusion Criteria ................................ ................................ ................................ ........  2-3 
2.5. Treatment Plan ................................ ................................ ................................ ...............  2-4 
2.5.1.  Randomization  ................................ ................................ ................................ ............  2-4 
2.5.2.  Ann Arbor Scoring  ................................ ................................ ................................ ...... 2-4 
2.5.3.  Sirolimus (rapamycin, Rapamune®)  ................................ ................................ ..........  2-5 
2.5.4.  Prednisone  ................................ ................................ ................................ .................  2-16 
2.5.5.  GVHD Prophylaxis Medications  ................................ ................................ ..............  2-17 
2.5.6.  Topical and Ancillary GVHD Therapies  ................................ ................................ .. 2-17 
2.5.7.  Management of study therapy after GVHD Progression or Non -response:  .............  2-17 
3. STUDY ENDPOINTS  ................................ ................................ ................................ .... 3-1 
3.1. Primary Endpoint  ................................ ................................ ................................ ..........  3-1 
3.1.1.  Response Definitions  ................................ ................................ ................................ .. 3-1 
3.2. Secondary Endpoints  ................................ ................................ ................................ ..... 3-1 
3.2.1.  Proportion of Patients with CR/PR and Steroid Dose 0.25 mg/kg or less  ..................  3-1 
3.2.2.  Proportion of response  ................................ ................................ ................................  3-2 
3.2.3.  Treatment Failure  ................................ ................................ ................................ ........  3-2 
3.2.4.  Incidence of Chronic GVHD  ................................ ................................ ......................  3-2 
3.2.5.  Incidence of Systemic Infections  ................................ ................................ ................  3-2 
3.2.6.  Event -Free Survival  ................................ ................................ ................................ .... 3-2 
3.2.7.  Disease -free and Overall Survival  ................................ ................................ ..............  3-3 
3.2.8.  GVHD -Free Survival  ................................ ................................ ................................ .. 3-4 
3.2.9.  Non-relapse Mortality  ................................ ................................ ................................ . 3-4 
3.3. Exploratory Endpoints  ................................ ................................ ................................ .. 3-4 
3.3.1.  Steroid Dose  ................................ ................................ ................................ ................  3-4 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
viii 3.3.2.  Topical Therapy  ................................ ................................ ................................ ..........  3-4 
3.3.3.  Discontinuation of Immune Suppression  ................................ ................................ .... 3-4 
3.3.4.  Incidence of EBV -associated lymphoproliferative disorder  ................................ ....... 3-4 
3.3.5.  Steroid - and sirolimus - associated complications (collected in all patients):  .............  3-4 
3.3.6.  CMV -reactivation  ................................ ................................ ................................ ....... 3-5 
3.3.7.  Patient -reported Outcomes  ................................ ................................ ..........................  3-5 
3.3.8.  AA3 Biomarker Outcomes  ................................ ................................ ..........................  3-6 
4. PATIENT ENROLLMENT AND EVALUATION  ................................ ....................  4-1 
4.1. Approaching Patients, Eligibility Screening and Obtaining Consent  .......................  4-1 
4.2. Enrollment/Randomization  ................................ ................................ ...........................  4-1 
4.2.1.  Treatment  ................................ ................................ ................................ ....................  4-1 
4.3. Study Monitoring  ................................ ................................ ................................ ...........  4-2 
4.3.1.  Follow -up Schedule  ................................ ................................ ................................ .... 4-2 
4.4. Assessments  ................................ ................................ ................................ ....................  4-4 
4.5. Weekly GVHD Monitoring  ................................ ................................ ...........................  4-8 
4.6. Adverse Event Reporting  ................................ ................................ ..............................  4-8 
4.6.1.  Required Adverse Event Reporting  ................................ ................................ ............  4-9 
5. STATISTICAL CORRELATIONS  ................................ ................................ .............  5-1 
5.1. Study Design  ................................ ................................ ................................ ...................  5-1 
5.1.1.  Accrual  ................................ ................................ ................................ ........................  5-1 
5.1.2.  Rando mization  ................................ ................................ ................................ ............  5-1 
5.1.3.  Primary Endpoint  ................................ ................................ ................................ ........  5-1 
5.1.4.  Primary Hypothesis  ................................ ................................ ................................ ..... 5-1 
5.1.5.  Sample Size and Power Considerations  ................................ ................................ ...... 5-2 
5.2. Interim Analysis and Stopping Guidelines  ................................ ................................ .. 5-3 
5.2.1.  Interim Analysis  ................................ ................................ ................................ ..........  5-3 
5.2.2.  Guidelines for Safety Monitoring  ................................ ................................ ...............  5-3 
5.2.3.  Demographic and Baseline Characteristics  ................................ ................................ . 5-5 
5.2.4.  Analysis of Primary Endpoint  ................................ ................................ .....................  5-6 
5.2.5.  Analysis of Secondary Endpoints  ................................ ................................ ...............  5-6 
5.2.6.  Analysis of Exploratory Endpoints  ................................ ................................ .............  5-7 
5.2.7.  Secondary Analysis of AA3 Patients:  ................................ ................................ .........  5-9 
5.2.8.  Exploratory Subgroup Analysis:  ................................ ................................ .................  5-9 
 
LIST OF APPENDICES  
 
APPENDIX A  HUMAN SUBJECTS  
APPENDIX B  LABORATORY PROCEDURES  
APPENDIX C  DIAGNOSIS AND SCORING OF ACUTE AND CHRONIC GVHD  
APPENDIX D  DERIVATION OF A SEQUENTIAL TEST STATISTIC FOR 
CENSORED EXPONENTIAL DATA  
APPENDIX E SUGGESTED PREDNISONE TAPER SCHEDULE  
APPENDIX F REFERENCES  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
1-1 CHAPTER 1  
 
 
1. BACKGROUND  AND RATIONALE  
 
1.1. Introduction  
 
Acute graft -versus -host disease (aGVHD) is a frequent complication of allogeneic hematopoietic 
cell transplantation (HCT) involving activation of donor T -lymphocytes against host tissues.1 
Despite immune suppression prophylaxis, up to 50% of HCT recipients will experience aGVHD 
of varying severity.2  The syndrome of aGVHD involves multiple target organs, including the 
skin (presenting most frequently as a maculopapular rash), intestinal tract (presenting as 
nausea/vomiting and/or diarrhea), and liver (presenting as choles tatic liver injury with or without 
transaminase elevation).  The mainstay of treatment of aGVHD for over 3 decades has been 
high-dose corticosteroids, typically dosed at the prednisone equivalent of 1 -2 mg/kg per day.3  
Corticosteroid therapy has several shortcomings, including both limited efficacy and toxicity 
including infection, hyperglycemia, hypertension, hyperlipidemia, and osteoporosis.   
 
One of the challenges that remains daunting in the clinical management o f allogeneic HCT 
recipients is knowing which patients are likely to have mild aGVHD who would possibly be 
spared the side effects of prolonged high doses of corticosteroids.  Different approaches to risk 
stratify patients with aGVHD have been recently deve loped and refined.  These strategies 
include models built upon initial clinical staging of aGVHD target organs (e.g., skin, intestinal 
tract, and liver) and blood biomarker -based approaches.  Both of these strategies hold value in 
identifying patients who are likely to respond well (i.e., demonstrate a complete response [CR] 
or partial response [PR]) to corticosteroids and thus less likely to die due to complication of the 
transplant (i.e., experience transplant -related mortality [TRM]).4  
 
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
1-2 1.2. Risk Stratification by Ons et Organ Severity  
 
In 1990, Weisdorf et al. identified in multivariate analyses that overall stage score (sum of each 
aGVHD organ stage 0 -4, plus 1 point for upper GI, for a maximum score of 13) was strongly 
associated with likelihood of CR.3  Based upon this initial observation that single organ 
involvement was more likely to achieve a CR than multi -organ involvement, the GVHD Risk 
Score was s ubsequently developed by the Minnesota group.5  Multivariate analysis of the 
outcomes of 864 consecutive patients from 1990 -2007 yielded the following high -risk organ 
stages:  skin stage 4, lower gastrointestinal stage 3+, liver stage 3+, or skin stage 3 and lower 
gastrointestinal or liver stage 2+ GVHD.   
 
The GVHD Risk Scor e has recently been refined using 
data from multiple centers as well as Blood and 
Marrow Transplant Clinical Trials Network (BMT 
CTN) clinical trials 0302 and 0802 6 with a total of 
1,723 patients used in modeling – the largest aGVHD 
cohort analyzed for t heir characteristics and outcomes 
to date. Developed using clinical grouping and 
recursive partitioning, this new Risk Score 
(http://z.umn.edu/MNAcuteGVHDRiskScore ) can 
classify patients into high -risk (HR) or standard risk at 
the onset of aGVHD symptoms.  In this model, 84% of 
patients are classified as standard risk , defined as 
single organ involvement (stage 1 -3 skin or stage 1 -2 
GI) or two organ involvement (stage 1 -3 skin plus 
stage 1 GI; or stage 1 -3 skin plus stage 1 -4 liver), with 
a day 28 CR/PR rate of 69% (Figure 1).  All others are considered HR, with a day 28 CR/PR rate 
of 43%.  This model can be used in real time at the bedside, making it practical for stratification 
in clinical trials.   
 
1.3. Risk Stratification by Blood Biomarkers  
 
Serum proteomic patterns associated with aGVHD were first 
published approximately 10 years ago7,8.  The University of 
Michigan group has significantly expanded the proteomic 
profiling of patients with aGVHD in recent years by 
developing a 3 -level risk stratificat ion system, Ann Arbor 1 
(AA1) low -risk aGVHD, Ann Arbor 2 (AA2) intermediate -
risk aGVHD, and Ann Arbor 3 (AA3) high -risk aGVHD.  
The Ann Arbor score is based upon serum or plasma levels of 
tumor necrosis factor receptor -1 (TNFR1), regenerating islet -
derive d 3-alpha (REG3α), and suppression of tumorigenicity 
2 (ST2) measured at diagnosis of GVHD, regardless of clinical 
severity (grades I -IV). Each Ann Arbor score corresponds to a 
distinct risk of six -month non -relapse mortality (NRM), such 
that Ann Arbor 1 G VHD has <10% NRM, Ann Arbor 2 
Figure 1.   Comparison of day 28 CR/PR in MN 
Standard vs. High Risk aGVHD patients.  
Figure 2.   Comparison of day 28 
CR/PR in AA1, AA2, and AA3 
biomarker -based risk stratified patients.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
1-3 GVHD ~25% NRM, and Ann Arbor 3 GVHD has >40% NRM.  The scoring algorithm was 
validated in an independent test set of patients with aGVHD from the University of Michigan 
and the University of Regensberg, and in a separate valid ation set from multicenter Blood and 
Marrow Transplant Clinical Trials Network (BMT CTN) aGVHD treatment trials 0302 and 
0802.9  Relapse rates do not differ between Ann Arbor scores and thus the differences in non -
relapse mortality translate into significant differences in survival. Differences in response to 
treatment account for the vast majority of differenc es in NRM.  Patients with AA1 demonstrate 
81% CR/PR at day 28 and AA2 patients demonstrate 68% CR/PR at day 28 (Figure 2).  In 
contrast, high risk AA3 patients demonstrate 46% CR/PR at day 28. Furthermore, treatment 
responses for patients with AA3 GVHD are  significantly less likely to be durable compared to 
AA1 and AA2 patients. Only 21% of AA3 patients remain in CR without flare at six months 
from diagnosis compared to 47% of AA1/2 patients (p<0.001). Importantly, similar proportions 
of patients are assign ed to each Ann Arbor score in each of the three standard groupings of 
Glucksberg grades (I vs. II vs. III/IV). Thus, approximately 20% of all newly diagnosed GVHD 
cases have a high risk biomarker profile. These patients have poor responses to primary 
treatment, experience high NRM even when the clinical presentation is not severe, such as a 
<50% skin rash. Given their high likelihood of treatment failure, these patients are not good 
candidates for steroid sparing primary GVHD treatment trials. While compell ing differences are 
observed in AA1/AA2 versus AA3 cohorts above, blood GVHD biomarkers have never 
previously been used to prospectively risk stratify patients.   
 
In February  2017 , the same group that developed the Ann Arbor scoring system published  that 
the concentrations of two biomarkers, ST2 and REG3α, measured on day 7 after HCT predicted 
lethal GVHD. This group, now located at Mount Sinai School of Medicine , developed and 
validated the MAGIC (Mount Sinai Acute GVHD International Consortium) algorithm  from 
1287 patients who received  an allogeneic HCT at 11 
different centers in the United States, Europe, and Asia 
[Hartwell JCI Insight  2017]. The MAGIC two biomarker 
algorithm is able to predict GVHD outcomes at multiple 
timepoints after HCT, including d ay 7, day 14 (unpublished 
data), at GVHD onset [Hartwell, JCI Insight 2017], and after 
one week of GVHD treatment with systemic steroids 
[Major -Monfried, ASH 2016]. As shown in the figure, the 
MAGIC algorithm generates Ann Arbor scores with the 
same risk f or NRM as the three biomarker algorithm, but 
more patients are assigned to the low risk group (Ann Arbor 
1) and the high risk group (Ann Arbor 3) than with the three biomarker algorithm. As of April 7, 
2017 no patient’s classification as AA1/2 or AA3 would  have changed if the MAGIC algorithm 
had been used since the activation of BMT CTN 1501 . Thus, given its advantages  for design of 
future GVHD clinical trials incorporating biomarkers and the lack of impact on this study , the 
MAGIC algorithm will replace the three  biomarker algorithm  for determining Ann Arbor risk 
status.  
 
1.4. Results of Previous aGVHD Therapy Trials  
 

Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
1-4 To date, two multicenter aGVHD treatment trials have been conducted in the Blood and Marrow 
Transplant Clinic al Trials Network (BMT CTN).  The first, BMT CTN 0302, was a multicenter, 
randomized, four -arm phase II trial that was designed to identify the agent most promising for 
use in addition to corticosteroids for the front -line therapy of aGVHD.  180 patients w ith a new 
diagnosis of aGVHD were randomized between the addition of etanercept, mycophenolate 
mofetil (MMF), denileukin diftitox, or pentostatin.  The proportion of day 28 CR/PR was highest 
in the MMF arm at 60%.10  Thus, MMF was selected for a randomized phase III trial of  MMF 
versus placebo for first -line therapy of aGVHD in the subsequent study, BMT CTN 0802.  In 
CTN 0802, MMF did not meet the primary endpoint of extending GVHD -free survival at day 56 
at a planned interim analysis of 235, and the trial was terminated for futility.11  Day 28 CR/PR 
was approximately 50% in both arms of this study, with no statistically significant difference 
between the two.  Neither BMT CTN 0302 nor 0802 were risk -stratified according to clinical or 
biomarker -based strategies.  
 
1.5. Sirolimus as Primary, Steroid -Free aGVHD Therapy  
 
A retrospective analysis was conducted to examine activity of sirolimus as a sole, steroid -free, 
acute GVHD therapy.12 A total of 32 HCT recipients with new onset acute GVHD treated a t the 
Moffitt Cancer Center were included. Median age was 60 (range 28 -73), 72% were not in 
remission from their malignancy at time of HCT, and original GVHD prophylaxis consisted of 
tacrolimus/methotrexate (n=29), or tacrolimus/mycophenolate mofetil (n=3) . Patients were 
treated with sirolimus as the primary therapy for acute GVHD at median of 30 (range 15 – 106) 
days after HCT. Acute GVHD was biopsy confirmed in 31/32 cases, and included a 
representative mix of target organ involvement (skin 17, 53%; GI 21 , 66%, and liver 5, 16%). 
Overall grade was I (n=4, 13%), II (n=24, 75%), or III (n=4, 13%). None had overall grade IV. 
When evaluated according to Minnesota risk stratification, 27 (84%) were standard risk and 5 
(16%) were high risk. Sirolimus was adminis tered orally as a median loading dose of 6mg (range 
2 to 9 mg), followed by maintenance dosing to sustain the desired target therapeutic levels (5 -
14ng/mL). Tacrolimus was decreased to target a range between 3 -7 ng/ml. This approach was 
safe, and thromboti c microangiopathy (TMA) was infrequent (n=3 cases total). Per BMT CTN 
consensus criteria, this was grade 1 in one case, and grade 2 in two cases. TMA resolved with 
dose reduction of tacrolimus in all cases.  
 
Sixteen (50%) patients achieved CR of acute GVHD  (defined as sustained complete resolution 
GVHD for 4 weeks without addition of prednisone or other systemic immune suppressive 
agents) following primary therapy with sirolimus. Among these 16 patients who achieved 
complete resolution of acute GVHD with si rolimus alone, initial overall response (composite of 
partial and complete response) was achieved at median of 7 days (range 5 – 21 days) and 
complete response was achieved by a median of 14 days (range 5 – 28 days). In two of these 
cases, recurrent acute GVHD developed 7 – 12 weeks after initial CR; resolution of recurrent 
acute GVHD was achieved in both with the addition of 0.2 – 0.5 mg/kg body weight of 
prednisone.  
 
In the remaining 16 cases, systemic glucocorticoids were initiated at a median of 9 days  (range 2 
– 28 days) after initiation of sirolimus with a prednisone -equivalent median dose of 0.5 (range 
0.2 – 1) mg/kg, and 12 achieved resolution of acute GVHD. Uniform criteria for initiation of 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
1-5 systemic steroids after first line sirolimus were not emp loyed. Prednisone was started for 
persistent acute GVHD manifestations of unchanged severity in 6 cases (median 9 days from 
sirolimus initiation, range 2 -19 days), grade progression in 6 cases (median 9 days from 
sirolimus initiation, range 2 -16 days), in the setting of partial response in 2 cases (6 -7 days after 
sirolimus initiation), and in 2 cases for recurrent acute GVHD within 4 weeks after initial 
complete response to sirolimus. Four (12%) had persistent acute GVHD that was treated with 
mycophenolate mofetil. Of these four patients, one died following primary disease relapse, two 
died from non -relapse causes (sepsis, and refractory acute GVHD with sepsis), and one survived.  
 
A matched cohort treated with standard (1mg/kg/day starting dose) prednisone for acute GVHD 
was assembled. These were matched to the primary sirolimus therapy cohort according to acute 
GVHD organ involvement and severity, as well as HLA matching, donor, graft source, and 
initial GVHD prophylaxis. Nineteen of these 32 subjects (59%)  achieved complete remission, as 
compared to 16/32 (50%) of those treated with sirolimus primary therapy (p=0.47). In total, these 
data support safety and activity of sirolimus as a steroid -free primary therapy for acute GVHD.  
 
1.6. Study Rationale:  
 
Advances are needed in primary therapy of acute GVHD, as standard corticosteroid therapy is 
incompletely successful and associated with toxicity. Additionally, a growing body of evidence 
suggests that standard -risk GVHD patients can be identified using clinical and  biomarker -based 
risk stratification tools. Lower -intensity therapy may be effective and spare toxicity in this 
setting. Existing data support safety and activity of sirolimus as a sole, steroid -free primary 
therapy in acute GVHD, however a prospective ran domized trial is needed. Using a combined 
risk stratification approach, we will select a standard -risk ( refined Minnesota standard risk, Ann 
Arbor 1/2 risk) acute GVHD population and conduct a randomized phase II trial examining acute 
GVHD response rates a fter primary therapy with either  sirolimus or standard prednisone 
(2mg/kg/day starting dose, followed by taper) therapy.  
 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-1 CHAPTER 2  
 
 
2. STUDY DESIGN  
 
2.1. Study Overview  
 
The study is a multicenter, Phase II, randomized trial assessing  sirolimus as primary therapy for 
standard -risk ( refined Minnesota standard risk, Ann Arbor (AA) 1/2 biomarker risk) acute 
GVHD . This trial incorporates both a novel up front GVHD therapy (sirolimus) as well as a 
novel BMT CTN developed acute GVHD  biomarker. Given the two novel aspects of this trial , 
the purpose of the study is to estimate differences in response rates between for acute GVHD 
patients identified as standard risk by both clinical and biomarker risk assessment and  
random ized to siroli mus or prednisone. Secondary objectives will assess safety, measures of 
steroid burden and toxicity as well as  quality of life.  
 
2.2. Hypothesis and Specific Objectives  
 
2.2.1.  Primary Hypothesis  
The primary hypothesis is that sirolimus and prednisone will achieve co mparable Day 28 CR/PR 
rates in the treatment of standard -risk acute GVHD  (defined by both refined Minnesota clinical 
standard -risk criteria and AA1/2 biomarker risk group) . 
 
2.3. Study Objectives  
 
2.3.1.  Primary Objective:  
The primary objective is to assess the rate o f complete remission (CR)/ partial remission (PR) on 
day 28 post -randomization  in patients with standard -risk acute GVHD defined by both clinical 
and AA1/2 risk status. . 
 
2.3.2.  Secondary Objectives are to assess the following:  
1. The proportion of patients with an acute GVHD response on Day 28 (CR or PR) and who 
are on a prednisone (or prednisone dose -equivalent corticosteroid) dose of 0.25mg/kg/day 
or less.  
2. Proportions of CR, PR, mixed response, no response and progression among surviving 
patients at Day 14, 28 and 56.  
3. Treatment failure (treatment failure defined as: no response, progression, administration 
of additional therapy for GVHD beyond primary thera py, or mortality) at Day 14, 28, and 
56. 
4. Incidence of chronic GVHD by 6 and 12 months post -randomization.  
5. Incidence of systemic infections within 6 months of randomization.  
6. Freedom from acute GVHD progression, chronic GVHD, malignancy relapse and 
mortality  at 6 months and 12 months post -randomization.  
7. Disease -free and overall survival at 6 and 12 months post randomization.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-2 8. GVHD -free survival at 6 and 12 months post -randomization.   
9. Non-relapse mortality at 6 and 12 months post -randomization.  
 
2.3.3.  Exploratory  Objectives are to assess the following:  
1. Steroid -dose (measured in prednisone -equivalent) on Days 7, 14, 21, 28, 35, 42 and 56.  
2. Use of topical (skin, GI) agents for acute GVHD therapy.  
3. Incidence of discontinuation of immune suppression, and immune suppress ion 
discontinuation without GVHD or disease progression/recurrence by Days 56, 180, and 
365 post-therapy.  
4. Incidence of EBV -associated lymphoproliferative disorder or EBV reactivation requiring 
therapy  
5. Incidence of corticosteroid - and sirolimus -associated c omplications (collected in all 
patients):  
a. Incidence of hyperglycemia (defined as a random glucose >200mg/dL or fasting 
glucose >126mg/dL)  and use of diabetes therapy (use of insulin and/or oral 
medications to control and/or maintain glucose levels)  at bas eline, Day 28 and 
Day 56 . 
b. Change from baseline in functional myopathy score at Day 56 and 6 -months post -
randomization.  
i. Hip Flexor and Quadriceps Strength via handheld dynamometer  
ii. Two Minute Walk Test  
iii. 5-time Sit -to-Stand  
iv. Adult Myopathy Assessment Tool (AMAT )  
c. Incidence of hyperlipidemia as measured by fasting lipid panel at baseline, Days 
28, 56 and 180 post -randomization.  
d. Incidence of post -transplant thrombotic microangiopathy (TMA) by 6 months 
post-randomization.  
6. Proportion of patients requiring therapy fo r CMV -reactivation by day 56 post -
randomization.  
7. Change in patient -reported outcomes from enrollment to Day 56 , 6 months and 12 
months . 
a. MD Anderson Symptom Inventory (MDASI)  
b. FACT -BMT  
c. MOS Short Form 36 (SF -36)  
d. PedsQL (Pediatric patients)  
8. A secondary descriptive analysis will evaluate outcomes for AA3 patients.  
 
2.4. Patient Eligibility  
 
2.4.1.  Inclusion Criteria  
Biopsy of involved organs with acute graft -versus -host disease (GVHD) is encouraged, but not 
required for study entry. Enrollment /randomization includes commitment to continue steroids or 
sirolimus as specified in the protocol, as well as the required follow -up observations.  If, 
according to institutional practice, the intention to treat a patient depends on histologic results, 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-3 the patient should not be e nrolled on the BMT  CTN 1501 study, until the biopsy results are 
available .  Patients can be enrolled with only a clinically established diagnosis. If an unexpected 
biopsy result is reported, the treating physician/center should contact the protocol chair(s ) to 
discuss further course of action.  
1. Patients with  their first presentation of standard -risk acute GVHD , according to refined 
Minnesota Criteria. Refined Minnesota Criteria are available at 
https://redcap.ahc.umn.edu/surveys/?s=bNmFhseJIf . Standard -risk acute GVHD  
according to the refined Minnesota Risk Criteria  requires meeting one of the criteria 
below6: 
a. Single organ involvement  
i. Stage 1-3 skin  
ii. Stage 1 u pper GI 
iii. Stage 1-2 lower GI 
b. Multiple  organ involvement  
i. Stage 1-3 skin plus  stage 1 upper GI 
ii. Stage 1 -3 skin plus stage  1 lower  GI 
iii. Stage 1 -3 skin plus stage 1 lower GI plus stage 1 upper GI  
iv. Stage 1 -3 skin plus stage 1-4 liver  
v. Stage 1 lower GI plus stage 1 upper GI.  
2. Acute  Minnesota Standard Risk GVHD requiring systemic immune suppressive therapy.  
3. Acute GVHD developing after allogeneic hematopoietic cell transplantation using either 
bone marrow, peripheral blood, or umbilical cord blood.  Recipients of non -
myeloablative, reduced intensity conditioning and myeloablative transplants are eligible. 
All allogeneic donor sources are  permitted, including siblings, unrelated donors, HLA -
haploidentical related donors and umbilical cord blood.  
4. Patients that have never receiv ed systemic immune suppressive therapy for treatment  of 
active GVHD (topical skin and GI corticosteroids are allowe d). 
5. Ability to tolerate oral or enterically -administered medications . 
6. Patients of all ages .   
7. Absolute neutrophil count (ANC) greater than 500/µL.  
8. Biopsy confirmation of GVHD is not required.  Enrollment should not be delayed for 
biopsy or pathology result s unless local institutional practice mandates biopsy 
confirmation to make a GVHD treatment decision.  
9. Written informed consent and/or assent from patient, parent or guardian.  
10. Collection of a 5 ml blood sample (red top for serum) from the patient for Ann Arbor 
Scoring and ready to be shipped immediately after randomization.  
 
2.4.2.  Exclusion Criteria  
1. Patients receiving sirolimus (for any indication including GVHD prophylaxis) within 14 
days of screening for enrollment.  
2. Relapsed, progressing or persistent malignancy requiring withdrawal of systemic immune 
suppression.  
3. Patients with acute GVHD developing after a donor lymphocyte infusion.  
4. Active or recent (within 7 days) episode of transplant associated microangiopathy.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-4 5. Patients with uncontrolled infections will be excluded.  Infections are considered 
controlled if appropriate therapy has been instituted and, at the time of enrollment, no 
signs of progression are present.  Progression of infection is defined as hemodynamic 
instability attributable to sepsis, new symptoms, worsening physical signs or radiographic 
findings attribu table to infection. Persisting fever without other signs or symptoms will 
not be interpreted as progressing infection.  
6. Patients unlikely to be available for evaluation at the transplant  center on Day 28 and 56 
of therapy.  
7. A clinical presentation resembling de novo chronic GVHD or overlap syndrome (as 
defined in Appendix C) developing before or present at the time of enrollment.  
8. Patients receiving systemic corticosteroids for any indicati on within 7 days before  the 
onset of acute GVHD, except the following:  Stable replacement doses of corticosteroids 
for adrenal insufficiency are permitted (e.g. hydrocortisone total dose of 10 -12 
mg/m2/day or prednisone 5 -7.5mg daily or equivalent). Corti costeroids administered as 
premedication before transfusion of blood products or before intravenous medications to 
prevent infusion reactions are allowed.  
9. Patients who are pregnant  or breastfeeding . 
10. Females of childb earing potential (FCBP) or a man who ha s sexual contact with a FCBP  
and is  unwilling to use effective birth control for the duration of the study.   
11. Patients on dialysis.  
12. Patients on mechanical ventilation.   
13. Patients with severe hepatic sinusoidal obstruction syndrome who in the judgment of the 
treating physician are not expected to have normalized bilirubin by Day 56 after 
enrollment.  
14. Patients with a history of hypersensitivity to sirolimus or any component of the 
formulation.  
 
2.5. Treatment Plan  
 
2.5.1.  Randomization  
A 5 mL blood sample (red top tube)  for Ann Arbor Scoring mus t be collected from the patient 
prior to enrollment/randomization in AdvantageEDC  (see section 2.5.2) .  Upon confirmation of 
eligibility in AdvantageEDC , the study participant will be randomized in a 1:1 fashion to receive 
either sirolimus or prednisone.  Study treatment (sirolimus/prednisone) should be initiated as 
soon as possible after randomization.  A maximum of 24 hours from randomization to first d ose 
of study medication is allowable.   
 
2.5.2.  Ann Arbor Scoring  
Immediately after randomization , the 5 ml of blood (red top for serum) will be shipped priority 
overnight for early morning arrival at the Biomarker Laboratory of  the Icahn School of Medicine 
at Mo unt Sinai  for biomarker analysis. Samples can be shipped Monday to Friday, and results 
can be delivered Tuesday through Saturday. Once received in the laboratory, the GVHD 
biomarkers used to assign the Ann Arbor GVHD score will be measured by ELISA using 
standard technical procedures in a CLIA certified laboratory. Processing the sample, measuring, 
and confirming the ELISA assay results take 4.5 hours (range 4 -6 hours). Once the Ann Arbor 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-5 score is confirmed, the investigator at the participating center will  be notified if the patient has 
AA1/2  biomarker risk, AA3  biomarker risk  or missing biomarker results . Notification  of the 
patient’s Ann Arbor results  will occur within 72 hours of study enrollmen t/randomization  
(usually within 48 hours).  
 
Those with AA1 /2 status will remain on their randomized therapy .  AA3 patients and patients 
with missing biomarker results can continue on the ir randomized therapy, or another  therapy , per 
the discretion of the treating physician .  All patients, regardless of treatment re ceived or  
biomarker status, must  complete all planned study assessments. Patients with AA1/2 biomarker 
status and clinical standard risk will be included in the analysis for the primary endpoint. In 
contrast, patients with AA3 status  or missing biomarker s tatus will not be considered for the 
primary analysis, but will be included as  a secondary descriptive analysis.  GVHD response and 
therapy used in patients with  AA3 status  may be used in exploratory analyses to generate 
hypotheses for future high risk GVHD  trials.  
 
2.5.3.  Sirolimus (rapamycin, Rapamune®)  
Drug Information  
Description, Administration and Storage  
Sirolimus is a naturally occurring compound produced by Streptomyces hygroscopicus.  In 
addition to its immunosuppressive properties, sirolimus has antifungal, antiviral and 
antineoplastic properties.  
*Patients can be treated with either Rapamune (sirolimus) or generic sirolimus, however it is 
strongly recommended to use one of these agen ts consistently throughout the therapy period.  
 
1) Oral solution :  
Sirolimus oral solution is supplied in cartons of 2 oz (60 mL fill) amber glass bottles, or 
foil pouches.  The oral solution contains sirolimus at a concentration of 1 mg/mL and the 
follow ing inactive ingredients: Phosal 50 PG (phosphatidylcholine, propylene glycol, 
monodiglycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80.  
The oral solution also contains 1.5% - 2.5% ethanol.  The appropriate dose of sirolimus  
oral solution should be measured using the provided amber colored oral syringe and is 
diluted in at least 2 oz (1/4 cup) of water or orange juice to improve palatability.  No 
other liquids, including grapefruit juice, should be used for dilution.  After v igorous 
mixing, the diluted dose should be taken immediately.  Refill the container with an 
additional volume (recommended minimum of 4 oz (1/2 cup) of water or orange juice), 
stir vigorously, and drink or administer at once to assure delivery of all of th e medication.  
Small children may not be able to consume the recommended volumes of water or orange 
juice suggested for dilution and may need lesser volumes.  
 
Sirolimus oral solution provided in bottles may develop a slight haze when refrigerated.  
If such a haze occurs allow the product to stand at room temperature and shake gently 
until the haze disappears.  The presence of this haze does not affect the qualit y of the 
product. Rapamune® Oral Solution bottles and pouches should be stored protected from 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-6 light and refrigerated at 2 C to 8C (36F to 46F).  The syringe should be discarded after 
one use.  After dilution, the preparation should be used immediately.   
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-7 2) Tablets :  
Sirolimus tablets are available as white, tan or yellow -to-beige triangular -shaped tablets 
marked “RAPAMUNE 1 mg,” “RAPAMUNE 0.5 mg” or “RAPAMUNE 2 mg” 
respectively, in bottles containing 100 tablets or cartons containing 10 blister cards eac h 
with 10 tablets (0.5 mg and 1 mg formulations only).  Each tablet contains sirolimus and 
the following inactive ingredients: sucrose, lactose, polyethylene glycol 8000, calcium 
sulfate, microcrystalline cellulose, pharmaceutical glaze, talc, titanium dio xide, 
magnesium stearate, povidone, poloxamer 188, polyethylene glycol 20,000, glyceryl 
monooleate, carnauba wax, and other ingredients.  The 0.5 mg and 2 mg tablets also 
contain yellow iron (ferric) oxide and brown iron (ferric) oxide.  Sirolimus tablets should 
be stored at 20  to 25C (68 - 77F).  Cartons should be used to protect blister cards and 
strips from light.  Sirolimus tablets should be dispensed in a tight, light -resistant 
container.  Sirolimus tablets should not be split or crushed.  
 
3) Pharm acology : 
The absorption of sirolimus is rapid after administration of Rapamune  Oral Solution, 
with a mean T max of 1-2 hours in different study populations. Oral bioavailability is only 
14% in stable renal transplant patients due to first pass metabolism i n the liver and the 
intestinal wall, plus counter transport in the gut lumen by P -glycoprotein. Mean 
bioavailability of sirolimus after administration of the tablet is about 27% higher relative 
to the oral solution. However, clinical equivalence has been d emonstrated for the 2 -mg 
dose.  Co -administration with high fat meals leads to reduced C max, prolonged T max 
and increased AUC, meaning that sirolimus should be taken consistently with or without 
food. The distribution of sirolimus is notable for extensive partitioning into blood cells 
and approximately 92% is bound to human plasma proteins.  Sirolimus is a substrate for 
CYP3A4 and P -glycoprotein, and is extensively metabolized by O -demethylation and/or 
hydroxylation to at least 7 major metabolites.  The par ent compound contributes to more 
than 90% of the immunosuppressive activity.  The excretion of Sirolimus is 91% fecal 
and only 2.2% via the urine.  
 
Whole blood sirolimus trough levels in renal transplant recipients who were administered 
daily doses of 2 mg  or 5 mg at 4 hours after Neoral®) were 8.59 ± 4.01 ng/mL and 17.3 ± 
7.4 ng/mL, respectively, as measured by LC/MS/MS.  Whole blood trough levels 
significantly correlated with steady state AUC (r 2=0.96).  Six days of multiple dosing 
were required to achiev e steady state.  Alternatively, a loading dose of three times the 
maintenance dose will provide near steady state concentrations within one day in most 
patients.  
 
The mean  SD terminal elimination half life (T 1/2) of sirolimus after multiple dosing in 
stable renal transplant patients was 62  16 hours.  The mean T 1/2 increased from 79  
12 hours in subjects with normal hepatic function to 113  41 hours in patients with 
impaired hepatic function.  Dosage reduction  is recommended for patients with mild to 
moderate hepatic impairment.  Limited pharmacokinetic data are available in pediatric 
patients with chronically impaired renal function but indicates similar T max (0.62 -1.6 h) 
and T 1/2 (31-111h).  Clearance is slow er in males compared to females but dose 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-8 adjustments based on gender are not recommended.  There were no differences between 
African Americans and non -African Americans.  
 
Sirolimus administration  
Patients randomized to sirolimus will receive a loading dose  after which a trough sirolimus level 
will be measured.  Based upon this sirolimus level, patients will either receive additional loading, 
or commence once daily maintenance sirolimus with levels checked routinely as described 
below.   
 
The initial loading  dose of sirolimus is required per protocol. Subsequent management of 
sirolimus dosing and adherence to intended therapeutic levels is strongly encouraged, but – due 
to inter -individual variation in drug metabolism and other factors – it is expected that d rug levels 
can’t be entirely kept within the desired range for all serial measures for all patients. In standard 
practice, frequent adjustment of sirolimus dosing is needed to achieve and maintain desired 
therapeutic levels. Thus, variation in actual dose of sirolimus and sirolimus drug levels over time 
will not be considered protocol deviations. The recommended dosing and drug levels serve as a 
practice guideline, not a protocol mandated procedure. These rules apply to dosing and 
monitoring of tacrolimus a nd cyclosporine on trial as well.  
 
Sirolimus Loading dose   
The loading dose of sirolimus is as follows:  
Patients >12 years of age: 6 mg PO once  
Patients ≤12 years of age:  5 mg/m2/dose PO once (max 6 mg PO once)  
 
Patients on voriconazole should reduce the loading dose by 50% - 90%, according to institutional 
practice.  
Patients on  posaconazole , isavuconazole and fluconazole  should receive 50% of recommended 
loading dose . 
 
Sirolimus Level after Loading Dose  
A trough sirolimus level should be performed promptly  after the loading dose (within 24 -48 
hours) .  Both initial and subsequent sirolimus level monitoring can be done both at centers 
participating in this protocol (if levels can be resulted within 48 hours) or through an external 
laboratory (also to result levels within 48 hours of receiving the sample). Study centers will work 
with the protocol team to ensure this is possible 7 days per week. The target serum sirolimus 
level after the loading dose is 10 -14 ng/mL.  The following is a management guidel ine based 
upon the initial sirolimus level:  
Level  Management  
< 5 ng/mL  Re-load with same loading dose  
5- <10 
ng/mL  Re-load with 50% of initial loading dose  
10-14 ng/mL  Move to maintenance dosing  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-9 >14 ng/mL  Hold sirolimus and recheck level daily. Start 
maintenance therapy when level is < 14ng/mL  
 
Initial planned maintenance dose  (revised as needed based on observed sirolimus levels):  
Patients >12 years of age: 2mg PO once daily  
Patients  ≤12 years of age: 2 mg/m2/dose PO once daily (max 2mg daily)  
 
Patie nts on voriconazole , posaconazole  or isavuconazole  should receive 10% of recommended 
maintenance dose (as an initial dose adjustment). Subsequent dose modification to maintain 
desired therapeutic levels will be tailored to each individual patient.  When calculating dosing, 
review medication list for  poten tial drug interactions.  CYP -450 and p -glycoprotein drug 
interactions.  See other dose modifications in sections below.  
 
Maintenance Sirolimus Levels   
Adults:  Sirolimus levels should be performed twice weekly until at steady state, then weekly for 
the sirolimus therapy  duration.  For dose changes, recheck sirolimus level after 3 days of therapy 
at new dose.  
Pediatrics:   Due to variability in the half -life of sirolimus in children < 12 years old, levels 
should be checked Monday, Wednesday and Friday unti l 2 consistent levels, then weekly.   For 
dose changes, recheck sirolimus level after 3 days of therapy at new dose.  
 
Maintenance Sirolimus level goals:  
- Target sirolimus level from outset through resolution of acute GVHD is 10 -14ng/mL.  
Level  Management  
< 5 ng/mL  Re-load with 50% loading dose and increase 
maintenance sirolimus dose by 10 -25%  
5 - <10 ng/mL  Increase sirolimus dose by 10 -25% 
10-14 ng/mL  Continue on current dose and repeat in 1 week  
>14 ng/mL  Hold sirolimus and recheck level daily.  
Resume therapy when level is < 1 4 ng/mL.  
▪ Initial level >14-20 ng/mL:  Resume therapy at 10 -25% lower dose  
▪ Initial level > 20 ng/mL:  Resume therapy at 25 -50% lower dose  
- After acute GVHD is completely resolved, the target therapeutic range can be decreased 
to 5-10ng/mL  
Level  Management  
< 5 ng/mL  Re-load with 50% loading dose and increase 
maintenance sirolimus dose by 10 -25%  
5-10 ng/mL  Continue  current dose and repeat in 1 week  
>10 - 14 
ng/mL  Decrease current dose  by 10 -25% and repeat 
in 1 week  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-10 >14 ng/mL  Hold sirolimus and recheck level daily.  
Resume therapy when level is < 10 ng/mL.    
▪ Initial level 11 -14 ng/mL:  Resume therapy at 10 -25% lower dose  
▪ Initial level > 1 4 ng/mL:  Resume therapy at 25 -50% lower dose  
Duration of Sirolimus : 
All patients should receive therapeutic sirolimus until at least day 56 after initiation .  
Thereafter, the decision of when and how to taper is at the discretion of the treating physician.  
Suggested Sirolimus Taper:  
The following is a suggested sirolimus t aper after completion of the required period of therapy:  
Reduce dose by 1/3 dose per month to complete taper off over 3 months.    
Sirolimus therapy guidance:  
• Sirolimus tablets should not be crushed, split or chewed.  
• It is recommended to not administer oral  suspension via NG or NJ, as this can obstruct 
the tube . Administration by G or J tube is acceptable.  
• To minimize the variability of exposure to sirolimus, it should be taken at a consistent 
time of day and consistently with or without food.  
• Fatty foods i ncrease overall absorption (AUC).  
• Sirolimus solution (1 mg/ml) may be mixed with ¼ cup of water or orange juice (no other 
liquids should be used ). Cup should than be refilled with another 1/2 cup of water of 
orange juice, stirred vigorously, and then admin istered.  
• Sirolimus solution may also be inserted in a gelatin capsule using a tuberculin syringe.  
• Sirolimus should not be taken within  4 hours after administration of Neoral® (or 
Gengraf®)  cyclosporine oral solution and/or cyclosporine gelatin capsules because 
premarketing studies in healthy volunteers demonstrated 116% -512% elevations of mean 
Cmax and 148% -230% elevations in AUC when sirolimus oral solution or tablets were 
simultaneously administered with Neoral but not when the doses were separated by 4 
hours.  
• Grapefruit juice  reduces CYP3A4 -mediated metabolism of sirolimus and must not be 
administered with sirolimus or used for dilution.  
• Extreme caution when subject is on voriconazole therapy (see section 2. 5.3.4) 
• Emesis : The sirolimus dose may be repeated within 15 minutes of a vomited dose.  
• Impaired renal function  does not mandate dosage adjustment.   
• Impaired hepatic function should prompt consideration for sirolimus maintenance doses 
to be reduced but no dose adjustm ent of the loading dose is necessary. Maintenance 
doses of sirolimus may be reduced by approximately one third in patients with hepatic 
impairment (Child -Pugh Score of ≥ 7/15 based on the sum of 1, 2 and 3 points 
respectively for each of: serum bilirubin i n mg/dL (< 2, 2 -3, > 3), serum albumin in 
mg/dL (> 3.5, 2.8 -3.5, < 2.8), INR (< 1.7, 1.71 -2.2, >2.2), hepatic encephalopathy (none, 
grade I -II, grade III -IV), or ascites (none, slight, moderate/refractory).  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-11 • Interchangeability of oral solution and tablets:  Two-milligram Rapamune Oral 
Solution is clinically equivalent to 2 -milligram Rapamune oral tablets; hence, are 
interchangeable on a milligram to milligram basis.  However, it is not known if higher 
doses of Rapamune Oral Solution are clinically equivalent  to higher doses of tablets on a 
milligram to milligram basis  
 
Expected toxicity and management guidelines  
TABLE 1.  SIROLIMUS TOXICITIES  
 Common  
>20%  Occasional  
2-20% Rare  
<2% 
Immediate  
Within 1 -2 days of 
receiving drug  Headache (L), hypertension 
(L), nausea, diarrhea, 
immuno -suppression (L), 
fever, constipation  Chest pain, insomnia, 
dyspepsia, vomiting, dyspnea  Hypotension, asthma, increased 
cough, flu like syndrome, 
tachycardia, anorexia, 
hypersensitivity reactions  
(exfoliative dermatitis, 
angioedema)  
Prompt  
Within 2 -3 weeks, 
prior to the next 
course  Tremor (L), renal 
dysfunction, elevated 
creatinine/BUN, anemia, 
pain (abdominal, back, 
pain), hyperlipidemia , 
hypercholesteremia, 
hypertrigylceridemia, 
hyperglycemia, peripheral 
edema , weight gain, 
arthralgia  Elevated LFTs (with elevated 
sirolimus levels), stomatitis, 
urinary tract infections, URIs, 
mild thrombocytopenia , 
leukopenia , 
hyper/hypokalemia (L), 
hypophosphatemia, rash, hives, 
pruritis, delayed wound 
healing o r dehiscence (L) , 
hypomagnesaemia (L), 
proteinuria  Opportunistic infections, pleural 
and pericardial effusions, non-
infectious pneumonitis or 
bronchiolitis -obliterans 
organizing pneumonia  and 
pulmonary fibrosis, thrombosis, 
myalgias, increased risk of CNI -
induced HUS/TTP/TMA (L)  
  
Delayed  
Any time later 
during therapy, 
excluding the above 
conditions  Acne   Chronic renal dysfunction, renal 
tubular necrosis, CHF, ascites, 
arthrosis, bone necrosis, 
osteoporosis  
Late  
Any time after 
completion of 
treatment    Lymphoproliferative disorders, 
skin malignancies  
Unknown 
Frequency and 
Timing  Sirolimus  was embryo/fetotoxic in rats at dosages of approximately 0.2 to 0.5; clinical doses were 
adjusted for body surface area. It is not known whether sirolimus  is excreted in human milk.  
(L) Toxicity may also occur later.  
Toxicities will be scored as per the NCI’s Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 , unless otherwise specified .  
 
• Hyperlipidemia: In the Phase III studies, treatment of new -onset hypercholesterolemia 
with lipid -lowering agents was required in 42 -52% of patients enrolled in the sirolimus 
arms.  Concomitant administration of sirolimus and HMG -CoA reductase inhibitors 
(statins) and/or f ibrates appeared to be well tolerated.  However, statins or fibrates should 
only be administered with caution to patients being treated with sirolimus and a CNI, at 
doses which are reduced according to label recommendations.  Treated patients should be 
monitored for the development of rhabdomyolysis.  Sirolimus should be continued during 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-12 therapy for hypercholesterolemia and hypertriglyceridemia unless the lipid levels are 
uncontrollable with standard therapy and are deemed to be at risk to the subject, per the 
treating physician.  
 
• Thrombotic Microangiopathy (TMA): Studies in adult transplant patients have shown an 
increase in TMA from 4.2% when patients were treated with tacrolimus or cyclosporine 
alone compared to 10.8% in patients treated with the tacrolim us/sirolimus combination.13  
TMA may occur both in the setting of sirolimus and/or CNI levels being above the 
therapeutic range or when levels are within desired ranges.  Although complete renal 
recovery occurred in 92% of these patients, the potential seriousness of this complication  
requires careful monitoring and management.  
 
To meet the definition (BMT CTN Consensus Definition) for TMA, a patient must have 
all of the following : 
1. RBC fragmentation and ≥ 2 schistocytes per high -power field on peripheral smear  
2. Concurrent increased ser um LDH above institutional baseline  
3. Concurrent renal* and/or neurologic dysfunction without other explanations  
4. Negative direct and indirect Coombs test results  
 
*Doubling of serum creatinine from baseline (baseline = creatinine before hydration 
and conditioning) or 50% decreased in creatinine clearance from baseline  
 
BMT  CTN Consensus for TMA severity scoring:  
 
Grade I  Evidence of RBC destruction (schistocytosis) without clinical 
consequences  
Grade II  Evidence of RBC destruction with increased creati nine ≤ 3 x ULN  
Grade III  Evidence of RBC destruction with creatinine > 3 x ULN not requiring 
dialysis  
Grade IV  Evidence of RBC destruction with renal failure requiring dialysis, and/or 
encephalopathy  
 
• Hematological Toxicity: ANC, hematocrit and platelet c ounts will be monitored at each 
visit. A thorough investigation should be made to assess for possible causes of the 
cytopenia (recurrent disease, infection, drug effect other than sirolimus, TMA, 
autoimmune hemolytic anemia/thrombocytopenia, GVHD, late eng raftment of platelets 
in cord blood transplant, etc.).  If other causes have been ruled out and cytopenias are 
significant (ANC<500, platelets <20K) sirolimus doses may be decreased by 50%.  If the 
cytopenia does not resolve after two weeks, sirolimus may be held.  If counts improve, 
restart sirolimus at 50% of dose and titer to full dose as tolerated.  
Sirolimus drug interactions, co -administration of calcineurin inhibitors, and dose -
modification for concurrent azole therapy  
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-13 Drug interactions:  
Sirolimus is  a substrate for cytochrome CYP 3A4 and a P -glycoprotein (P -gp).  
Drugs that may increase sirolimus blood concentrations include CYP 3A4, 5, or P -gp inhibitors:  
• Calcineurin inhibitors: Simultaneous administration of cyclosporine soft gelatin capsules 
(Neoral®) results substantial increases in the sirolimus Cmax and AUC.  This is avoided 
if sirolimus is taken 4 hours after administration of cyclosporine.  
• Calcium Channel Blockers: diltiazem, nicardipine, nifedipine, verapamil and amlodipine. 
Sirolimus sho uld be monitored and a dose adjustment may be necessary.  
• Triazole antifungal agents: fluconazole, itraconazole, clotrimazole,  posaconazole, 
isavuconazole voriconazole  and ketoconazole. The magnitude of increases sirolimus 
Cmax, tmax, and AUC is such that sirolimus should be administered cautiously together 
with fluconazole, itraconazole, or posaconazole, and with extreme caution if 
administered together with voriconazole  or isavuconazole .  If co -administration is 
unavoidable, then the dose of sirolimus should be greatly reduced at the time of initiation 
of the antifungal medication as recommended in Table 2 and that there should be very 
frequent monitoring of trough concentrations of sirolimus in whole blood.  Sirolimus 
concentrations should be measured upon initiation, during co -administration, and at 
discontinuation of antifungal treatment, with sirolimus doses adjusted accordingly.  
• Macrolide antibiotics: clarithromycin, erthyromycin, telithromycin, troleandomycin (but 
NOT azithromycin).  
• Gastrointestina l prokinetics: cisapride, metocloproramide.  
Drugs that may decrease sirolimus blood concentrations include CYP 3A4, 5, 7 or P -gp inducers :  
• Anticonvulsants: carbamazepine, Phenobarbital, phenytoin.  
• Antibiotics: Rifampin, rifanpentine.  
• Herbs: St. John’s Wor t (Hypericum perforatum ). 
Care should be taken when other drugs or substances that are metabolized by CYP3A4 or P -
glycoprotein are administered concomitantly with sirolimus.  Grapefruit juice reduced CYP3A4 
mediated metabolism of sirolimus and must not be used for dilution.  
 
Co-administration of calcineurin inhibitors:  
When co -administered with sirolimus, recommend target levels are as follows : 
 
The target serum level for tacrolimus  is 3-7 ng/mL  
  
The target serum level for cyclosporine  is 120-200 ng/mL  
 
Dose adjustments are based upon clinical judgment of the managing physician after considering 
clinical toxicity, serum levels, GVHD, concomitant drug use and the rate of rise or decline of the 
serum level. Following represent suggested  dose adjustments in calcineurin inhibitors, when 
initiating sirolimus to achieve target levels specified above.   
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-14 Calcineurin inhibitor actual  
serum level prior to 
initiating sirolimus  Recommended target  serum level 
for calcineurin inhibitors when co -
administered with sirolimu s Recommended dose 
adjustment to 
achieve 
recommended target 
serum level  
tacrolimus > 10 ng/mL  tacrolimus = 3 -7 ng/mL  50% dose reduction  
tacrolimus = 7.1 -10 ng/mL  tacrolimus = 3 -7 ng/mL  33% dose reduction  
tacrolimus ≤ 7.0 ng/mL  tacrolimus = 3 -7 ng/mL  No change  
cyclosporine > 400 ng/mL  cyclosporine = 120 -200 ng/mL  50% dose reduction  
cyclosporine = 201 -399 
ng/mL  cyclosporine = 120 -200 ng/mL  33% dose reduction  
cyclosporine ≤ 200 ng/mL  cyclosporine = 120 -200 ng/mL  No change  
*When calcineurin  inhibitors (cyclosporine, tacrolimus) are given with prednisone (i.e. 
among patients not randomized to the sirolimus arm of this trial), standard practices are 
recommended for dosing/monitoring of these agents . Suggested target levels for these agents 
in the absence of sirolimus are cyclosporine 200 -400ng/mL and tacrolimus 5 -15ng/mL. Again, 
these are recommendations (not protocol mandate d), and management is directed by the treating 
physician.  
 
Dose -modification in setting of azole therapy:  
Antifungal prop hylaxis: Triazole antifungal medications are expected to increase serum CNI and 
sirolimus levels, therefore, dosages of CNIs and sirolimus, should be adjusted accordingly using 
the guidelines recommended in Table 2 and 3.  
 
TABLE  2 - PRE -EMPTIVE DOSE RED UCT ION OF SIROLIMUS OR CNIs WHEN 
AZOLES ARE INITIATED  AT STEADY STATE LEV ELS OF SIROLIMUS OR CNIs 
Antifungal  Cyclosporine  Tacrolimus  Sirolimus  
 Dose  Dose  Dose  
Voriconazole  50% 67% 90% 
Posaconazole  25% 67% 90% 
Isavuconazole  50% 67% 90% 
Itraconazole  50% 50% ND 
Fluconazole  25% 25% 50% 
*Notes:  
1. If voriconazole must be added to control fungal infection then following the 90% reduction in 
sirolimus dosing14 and/or 50% -67% reduction in CNI dosing SRL and/or CNI serum levels should 
be measured 24 -48 hours later an d then every 3 -4 days until levels are stable and in the desired 
range.  If voriconazole is given intravenously or if voriconazole and sirolimus are not given 
together, these guidelines may not apply because the effect on bioavailability of sirolimus will be 
weaker.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-15 2. Note that sirolimus tablets should not be split or crushed.  Fractional dose of sirolimus may be 
achieved by drawing an appropriate volume of the 1 mg/mL oral liquid formulation into a 1 mL 
syringe and swallowed directly (or mixed with water or orange juice; no other liquids, including 
grapefruit juice, should be used for dilution).  
3. If posaconazole or itraconazole or high -dose fluconazole are added then SRL and/or CNI serum 
levels should be followed 48 -72 hours later and then every 3 -5 days until  levels are stable and in 
the desired range.  
 
TABLE 3 - ANTICIPATE DOSE I NCREASE OF SIROLIMUS  OR CNI s WHEN 
AZOLES ARE STOPPED D URING CONCOMITANT SI ROLIMUS OR CNI  THERAPY  
Antifungal  Cyclosporine  Tacrolimus  Sirolimus  
 Dose  Comment  Dose  Comment  Dose  Comment  
Voriconazole  2-fold Dose increase 
may not be 
necessary for     
5-10 days  3-fold Dose increase 
may not be 
necessary for     
5-10 days  10-fold Dose increase 
may not be 
necessary for     
5-10 days  Posaconazole  1.3-
fold 3-fold ND 
Isavuconazole  2-fold 3-fold 10-fold 
Itraconazole  2-fold 2-fold ND 
Fluconazole  1.3-
fold 1.3-fold 2-fold 
Note:    Although sirolimus and CNI doses may need to be substantially increased when azole therapy is stopped, the 
azole mediated inhibition of cytochrome CYP 3A4 (and other) and P -glycoprotein may take 5 -10 days to 
abate and therefore immediate dose increases are  not advised.  Rather, sirolimus and CNI dose increases 
should be cautious and based on more frequent monitoring of the sirolimus and/or CNI levels as appropriate.   
 
Additional considerations for calcineurin inhibitor (CNI) therapy:  
• Children  generally require a larger total daily dose of CNI by weight than adults. If aged 
< 6 years, every 8 hour administration may be required to maintain desirable serum 
trough levels. For those patients in whom adequate serum trough levels cannot be 
maintaine d using intermittent oral or IV dosing, continuous IV infusion may be 
warranted.  
• Review of concomitant medications for potential interactions that may significantly 
alter serum CNIs levels is essential  because  CNIs undergo extensive metabolism by the 
hepa tic and intestinal cytochrome P -450 system which may impact toxicity and efficacy 
of CNIs.   
• Although elevated CNI blood levels are more frequently associated with toxicity 
(especially renal or hepatic), “therapeutic” CNI blood levels may also be associate d with 
toxicity  (e.g. significant tremors). Therefore, dose decreases are recommended for 
significant organ toxicities that manifest despite a “therapeutic” CNI level.  
• Emesis : A repeat dose of CNI may be given if emesis happens within 15 minutes of 
taking the planned dose.  
• CNIs should be administered at a consistent time each day and in relation to meals.  
Neoral oral solution should be administered in orange or apple juice at room temperature.   
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-16 • Subjects should avoid beverages containing the enzyme bergam ottin  (grapefruit juice, 
Sunny Delight, Fresca, and Squirt) when taking CNIs.  
• Distal paraesthetic pain or burning during the infusion  may be alleviated by extending 
the IV infusion time for Sandimmune from the standard of 1 hour to as long as 6 hours. 
Alternatively, cyclosporine may be administered as a continuous infusion over 24 hours 
for patients intolerant of intermittent administration.  
• Monitor closely for an acute allergic reaction for the first 30 minutes after starting 
tacrolimus IV infusion and a t frequent intervals thereafter.   
• Intravenous route of administration is preferred for patients with progressive GVHD 
of the liver or gastro -intestinal tract  until GVHD is clinically improved and the oral 
route reliable.  
• If the oral route becomes temporarily unfeasible and conversion to the intravenous 
formulation is required the following recommendations are made:  
Starting Oral  
Formulation  Conversion to IV formulation  
Prograf®  IV Prograf = 0.25 x total daily dose of oral Prograf  but should be 
given as continuous daily infusion  
Neoral®  IV Sandimmune = 0.4 x total daily dose of Neoral  
Gengraf®  IV Sandimmune = 0.4 x total daily dose of Gengraf  
Sandimmune®  IV Sandimmune = 0.25 x total daily dose of oral Sandimmune  
 
2.5.4.  Prednisone  
Patients randomized to steroids will receive prednisone 2mg/kg/day PO (or methylprednisolone 
1.6 mg/kg/day IV).  Patients unable to take tablets can use oral prednisolone solution 2 
mg/kg/day.  For patients that weigh over 100kg, maximal starting dose of p rednisone will be 
200mg (or 2mg/kg based on a modified starting weight of 100kg). For calculation of subsequent 
prednisone doses/kg on subsequent measures, the modified starting weight of 100kg will be 
used.  
 
Duration of Steroids and Taper  
All patients sho uld receive prednisone 2mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day 
IV) for at least 3 full days (72 hours).  This starting dose was carefully selected for the following 
reasons:  (1) Both the clinical and biomarker -based risk stratification systems h ave been 
developed in the setting of patients treated with this starting prednisone dose; (2) The 
2mg/kg/day starting dose was used in both BMT CTN 0302 and CTN 0802 trials, and expected 
prednisone response rates and allied power calculations for this tria l are derived from this 
preliminary data; (3) Variable starting doses would confound the analysis of prednisone taper in 
this trial; (4) Prior randomized clinical trial data supported greater requirement for secondary 
systemic immune suppressive therapy in  those treated with 1mg/kg vs. 2mg/kg starting dose.15 
Thereafter  (after 72 hours of 2mg/kg/day dose) , the decision of when and how to taper is at the 
discretion of the treating physician.  A potential prednisone taper is provided in Appendix E. 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
2-17 2.5.5.  GVHD Prophylaxis Medications  
Medications such as cyclosporine  and tacrolimus (if used as GVHD prophylaxis when acute 
GVHD developed) should be continued at therapeutic doses adjusted as necessary fo r renal, 
central nervous system (CNS) or other toxicity using conventional management guidelines.   
 
2.5.6.  Topical and Ancillary GVHD Therapies  
Topical skin therapy for acute GVHD, including skin creams, as well as GI topical agents (e.g. , 
beclomethasone or bude sonide), are not encouraged on trial, however are not prohibited. Use of 
topical agents for management of acute GVHD will be recorded as a secondary endpoint 
assessment in this trial.  No rules or guideline for taper and discontinuation for topical agents is 
provided in this protocol.  
 
Ancillary/supportive care measures for acute GVHD such as the use of anti -motility agents for 
diarrhea, including octreotide, is allowed at the discretion of the treating physician.  Use of 
ursodiol to prevent/reduce gall bla dder sludging, or prevent hepatic transplant complications is 
also allowed according to institutional guidelines.  
 
2.5.7.  Management of study therapy after GVHD Progression or Non -response:  
The following guidelines describe intended management of initial randomiz ed therapy and 
thresholds for starting secondary therapy:  
 
1. Initial randomized therapy should be given for at least 4 days before considering initiation of 
secondary therapy. As progressive manifestations of GVHD (new organ involvement or 
increased organ  specific symptoms sufficient to increase the organ stage by one or more)  can be 
ultimately stabilized and controlled in this initial therapy timeframe, secondary therapy should 
only be considered if GVHD continues to progress after this period.  
 
2. If no  response (no improvement in any affected organ) is observed after 7 -10 days of initial 
randomized therapy, secondary therapy can be considered.  
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
3-1 CHAPTER 3  
 
 
3. STUDY ENDPOINTS  
 
3.1. Primary Endpoint  
The primary endpoint is the rate of complete remission (CR)/partial remissions (PR) on Day 28 
post-randomization  in patients with standard -risk acute GVHD (defined by both refined 
Minnesota clinical standard -risk criteria and AA1/2 biomarker risk group) .  Scoring of CR/PR 
are in comparison to the participant’s acute GVHD status (score) on the day of randomization.  
 
3.1.1.  Response Definitions  
Scoring of CR, PR, MR, NR and progression are in comparison to the participant’s acute GVHD 
status (score) on the day of ra ndomization.  
 
CR is defined as a score of 0 for the GVHD grading in all evaluable organs.   For example, 
for a response to be scored as CR at Day 56 or later, the participant must still be in CR on that 
day and have had no intervening additional therapy for  an earlier progression, PR or NR.  
 
Partial response (PR) is defined as improvement in one or more organs involved with 
GVHD symptoms without progression in others.   For example, f or a response to be scored as 
PR at Day 28 or later, the participant must s till be in PR on that day and have had no intervening 
additional therapy for an earlier progression, PR or no response (NR).  
 
Mixed response  (MR) is defined as improvement in one or more organs with deterioration 
in another organ manifesting symptoms of GVHD or development of symptoms of GVHD 
in a new organ.  
 
Progression is defined as deterioration in at least one organ without any improvement in 
others.  
 
No response (NR) is defined as absence of any improvement or progression as defined.  
Patients receivi ng secondary therapy (including need to re -escalate steroid dose to ≥ 2.5 
mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) will be classified 
as non -responders. Patients who are assigned to the sirolimus arm who require initiation  of 
systemic corticosteroids for the treatment of acute GVHD will be considered as non -responders 
for purposes of primary endpoint assessment.  
 
3.2. Secondary Endpoints  
 
3.2.1.  Proportion of Patients with CR/PR and Steroid Dose 0.25 mg/kg or less  
The proportion of pat ients with an acute GVHD response on Day 28 (CR or PR) and who are on 
a prednisone (or prednisone dose -equivalent corticosteroid) dose of 0.25mg/kg/day or less.  Note 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
3-2 that use of prednisone below the threshold on the sirolimus arm will not be considered a f ailure 
for this endpoint.  
 
3.2.2.  Proportion of response  
Proportions of CR, PR, mixed response, no response and progression among surviving patients at 
Day 14, 28 and 56.  
 
3.2.3.  Treatment Failure  
Treatment failure  is defined as: death, no response, progression, administration of additional 
therapy beyond primary therapy for GVHD ((or re -escalation of steroid dose to ≥ 2.5 mg/kg/day 
of prednisone (or methylprednisolone equivalent of 2 mg/kg/day) or initiation of corticosteroids 
for the treatment of acute GVHD for patients assigned to the sirolimus arm), at Day 14, 28, and 
56. 
3.2.4.  Incidence of Chronic GVHD  
Chronic GVHD is defined per NIH Consensus Criteria  (see Appendix C).  The incidence of 
chronic GVHD at 6 and 12 months post -randomization will be computed for each tr eatment arm, 
including organ involvement and severity, and overall global composite score 
(mild/moderate/severe).  
 
3.2.5.  Incidence of Systemic Infections  
All microbiologically documented infections or significant infections requiring 
antibiotic/antifungal therap y occurring after initiation of therapy will be reported by site of 
disease, date of onset, and severity.  For definitions see the BMT CTN MOP.   
 
3.2.6.  Event -Free Survival  
Event -free survival is defined here as freedom from acute GVHD progression, chronic GVHD, 
malignancy relapse and mortality at 6 months and 12 months post -randomization.  
 
Malignancy relapse is defined as follows :  
 
Relapse is defined by either morphological  or cytogenetic evidence of acute leukemia or MDS 
consistent with pre -transplant features, or radiologic evidence of lymphoma, documented or not 
by biopsy.   Progression of disease applies to patients with lymphoproliferative diseases 
(lymphoma or chronic l ymphocytic leukemia) not in remission prior to transplantation.   The 
event is defined as increase in size of prior sites of disease or evidence of new sites of disease, 
documented or not by biopsy.  
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
3-3 Acute leukemia and MDS  – Relapse will be diagnosed when  there is:  
- Reappearance of leukemia blast cells in the peripheral blood; or,  
- >5% blasts in the bone marrow, not attributable to another cause (e.g. bone marrow 
regeneration)  
- The appearance of previous or new dysplastic changes (MDS specific) within the bon e 
marrow with or without falling donor chimerism; or  
- The development of extramedullary leukemia or leukemic cells in the cerebral spinal 
fluid or  
- The reappearance of cytogenetic abnormalities present prior to transplantation  
 
Lymphoproliferative Diseases  – Relapse or progression will be diagnosed when there is:  
- Appearance of any new lesion more than 1.5 cm in any axis during or at the end of 
therapy, even if other lesions are decreasing in size.   Increased FDG uptake in a 
previously unaffected site will o nly be considered relapsed or progressive disease after 
confirmation with other modalities. In patients with no prior history of pulmonary 
lymphoma, new lung nodules identified by CT are mostly benign.   Thus, a therapeutic 
decision should not be made solel y on the basis of the PET without histologic 
confirmation.  
- At least a 50% increase from nadir in the sum of the product diameters of any previously 
involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or 
hepatic nodules ).  To be considered progressive disease, a lymph node with a diameter of 
the short axis of less than 1.0 cm must increase by  50% and to a size of 1.5 x 1.5 cm or 
more than 1.5 cm in the long axis.  
Lesions should be PET positive if observed in a typical  FDG -avid lymphoma or the 
lesion was PET positive before therapy unless the lesion is too small to be detected with 
current PET systems (<1.5 cm in its long axis by CT).  
- In addition to the criteria above, patients with CLL who present in complete remission  
prior to transplantation may fulfill the relapse definition if there is reappearance of 
circulating malignant cells that are phenotypically characteristic of CLL.  
 
*Institution of any therapy to treat persistent, progressive or relapsed malignancy, 
inclu ding the withdrawal of immunosuppressive therapy or donor lymphocyte infusion, 
will be considered evidence of relapse/progression regardless of whether the criteria 
described above were met.  
 
3.2.7.  Disease -free and Overall Survival  
Disease -free survival at 6 a nd 12 months post randomization. The events for disease -free 
survival are death and relapse of the underlying malignancy  (see above – section 3.2.6 - 
definition for relapse/progression) . Overall survival will be estimated at 6 and 12 months post -
randomizat ion. 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
3-4 3.2.8.  GVHD -Free Survival  
GVHD -free survival will be estimated at 6 and 12 months post -randomization.  Both acute and 
chronic GVHD will be considered in this estimate.  
 
3.2.9.  Non-relapse Mortality  
Non-relapse mortality at 6 and 12 months. The events for non -relap se mortality are death due to 
any cause other than relapse of the underlying malignancy.  
 
 
3.3. Explorato ry Endpoints  
 
3.3.1.  Steroid Dose  
Doses of methylprednisolone will be converted to prednisone equivalents by multiplying the 
methylprednisolone dose by 1.25.  The prednisone dose for each patient at Days 7, 14, 21, 28, 
35, 42 , 49, and 56 will be recorded. Prednisone doses for each patient will be converted to 
mg/kg. For patients that weigh over 100kg, maximal starting dose of prednisone will be 200mg 
(or 2mg/kg base d on a modified starting weight of 100kg). For calculation of subsequent 
prednisone doses/kg on subsequent measures, the modified starting weight of 100kg will be 
used. The cumulative prednisone dose for each patient at Day 56 will be calculated by adding the 
doses (end of each week’s dose) for each of the first eight weeks of treatment, divided by the 
number of days of survival during this interval.   
 
3.3.2.  Topical Therapy  
The proportion of patients using either topical skin or topical GI steroids will be calcu lated as a 
secondary endpoint.  Use of topical agents does not constitute systemic therapy, and does not 
result in designation of treatment failure.  
 
3.3.3.  Discontinuation of Immune Suppression  
The dates of discontinuation of corticosteroids and other systemic i mmune suppressive 
medications will be recorded. Incidence of discontinuation of immune suppression will be 
assessed at Days 56, 180, and 36 5 post-therapy. A composite endpoint of complete immune 
suppression discontinuation together with freedom from any GV HD or malignancy 
progression/recurrence will also be examined.  
 
 
3.3.4.  Incidence of EBV -associated lymphoproliferative disorder  
Incidence of EBV -associated lymphoproliferative disorder and EBV reactivation requiring 
therapy , such as reduction or withdrawal of immunosuppression, Rituximab or chemotherapy.  
 
 
3.3.5.  Steroid - and sirolimus - associated complications ( collected in all patients ): 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
3-5 Incidence of hyperglycemia  
Incidence of hyperglycemia (defined as a random glucose >200mg/dL or fasting glucose 
>126mg/dL)  and us e of diabetes therapy (use of insulin and/or oral medications to control and/or 
maintain glucose levels) at baseline, Day 28 and Day 56 . 
 
 
Functional Myopathy  
Change from baseline in functional myopathy score at Day 56 and 6 -month s post-randomization.  
i. Hip Flexor and Quadriceps Strength via handheld dynamometer  
ii. Two Minute Walk Test  
iii. 5-time Sit -to-Stand  
iv. Adult Myopathy Assessment Tool (AMAT)  
 
Hyperlipidemia  
Incidence of hyperlipidemia as measured by fasting lipid panel at baseline, Days 28, 56 and 180 
post-randomization.   The proportion of patients in each study arm with elevation outside of 
normal range for each of the measured components of the fasting lipid panel (e.g. total 
cholesterol, LDL, HDL, and triglycerides) will be compared .  Lipid parameters and us e of lipid -
lowering medications will be collected.    
 
Post-transplant thrombotic microangiopathy  
Incidence of post -transplant thrombotic microangiopathy (TMA) by 6 months post -
randomization. TMA definition is provided in section 2.5.3.3.  
 
3.3.6.  CMV -reactivation  
Proportion of patients requiring new systemic treatment for an increasing CMV PCR level per 
institutional practice (patients receiving only standard of care viral prophylaxis will not be 
included in this assessent)  for CMV -reactivation by Day 56 post -rando mization.  
 
3.3.7.  Patient -reported Outcomes  
These instruments will be completed by patients at enrollment, Day 56, 6 months , and 12 
months . Only English  speaking adult and pediatric patients,  and Spanish speaking adult patients 
are eligible to participate in the Health Quality of Life ( HQL ) component of this trial.  Patients 
>18 years will complete the FACT -BMT, MOS SF -36 and MDASI instruments . Patients > 8 
years through 18 years will complete the PedsQL™ Stem Cell Transplant Module.  Surveys are 
completed by participants using self -completed instruments as a first choice.  If this method of 
data collection is not possible, then surveys and response options may be read verbatim to 
participants, either in person or over the phone, to col lect data.  The method of survey 
completion, the date, and the language will be recorded in the database.  Surveys may not be 
completed by surrogates . 
 
Change in patient -reported outcomes from enrollment to Day 56 and 6 months will be calculated.  
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
3-6 a. MD Ander son Symptom Inventory (MDASI)  
 
The MDASI is a 19 item instrument that captures 13 symptoms (0=“not present” to 10=“as bad 
as you can imagine”) and 6 items measuring interference with life from 0 (“did not interfere”) to 
10 (“interfered completely”)16.    It provides two s ummary scales: symptoms and interference.  
The MDASI will be scored according to the recommendations of the developers.  We estimate it 
will take 5 minutes to complete the MDASI.  Surveys are completed by participants using self -
completed instruments as a first choice.  If this method of data collection is not possible, then 
surveys and response options may be read verbatim to participants, either in person or over the 
phone, to collect data.  Surveys may not be completed by surrogates.  
b. FACT -BMT  
 
The FACT -BMT, Version 4 is a self -administered instrument designed to assess multi - 
dimensional aspects of the QOL in BMT patients. It consists of the 27 -item FACT -General 
(FACT -G) and the 23 -item Bone Marrow Transplantation Subscale (BMTS).17 The FACT -G 
assesses four primary dimension s of QOL, including physical well -being (7 items), social/family 
well-being (7 items), emotional well -being (6 items), and functional well -being (7 items). A five 
point Likert -type response scale ranging from 0 to 4 is used (0 = 'not at all'; 1 = 'a little  bit'; 2 = 
'somewhat'; 3 = 'quite a bit'; and 4 = 'very much').  The original FACT -BMT was developed in 
English using a standardized approach for item derivation, reduction and testing, and has been 
used extensively in various clinical trials. The FACT -BMT  has since been translated into other 
languages.  
 
c. MOS Short Form 36 (SF -36)  
 
The MOS SF-36 Version 2 is a 36 -item self -report questionnaire which assesses patient -reported 
health and functioning.18 The instrument examines the following domains of QOL: physical 
functioning (PF), role functioning -physical (RP), bodily pain (BP), general health (GH), vitality 
(VT), social functioning (SF), role functioning -emotional (RE), and mental health (MH). Two 
summary scales from the SF -36 include the physical component score (PCS) and the mental 
component score (MCS).  
 
d. PedsQL  
 
The PedsQL measurement model for pediatric quality of life inventory is a multi -dimensional 
tool for monitoring health -related quality of  life (HRQOL) in children and adolescents (age 2 -
18).19 Age-specific versions for younger and older children are available. Physical, emotional, 
social, and school functioning are assessed. The PedsQL ™ Stem Cell Transplant Module is a 46 
item instrument that measures health -related quality of life in children and adolescents 
undergoing hematopoietic stem cell transplant, and is developmentally appropriate for self -report 
in ages 8 through 18 years.20 
 
3.3.8.  AA3 Biomarker Outcomes  
A secondary descr iptive analysis will evaluate outcomes for AA3 patients.  Patients with a 
missing AA result will be excluded.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-1 CHAPTER 4  
 
 
4. PATIENT ENROLLMENT AND EVALUATION  
 
4.1. Approaching Patients, Eligibility Screening and Obtaining Consent  
 
Patient s with previously untreated, standard -risk acute GVHD , according to the refined 
Minnesota Criteria , who are in need of systemic therapy, will be approached as soon as possible.  
Patients willing to participate in the trial will sign an Institutional Review  Board approved 
consent form.   Physicians will further evaluate each patient ’s eligibility for randomization onto 
this study (see Section 2.4).  
 
4.2. Enrollment /Randomization  
 
Patients will be enrolled/ randomized onto the study using the BMT CTN Advantage Ele ctronic 
Data Capture (EDC).  Patients will be randomized to Sirolimus versus Prednisone in a 1:1 ratio.  
The following procedures shall be followed:  
1. An authorized user at the clinical center completes the initial screening by entering 
patient demographics and Segment A information ( consent date , inclusion/exclusion 
criteria  and confirmation that 5 mL of blood has been collected for Ann Arbor Scoring ) 
on the Eligibility Form.  
2. If the patient is eligible, a study number and random treatment assignment is generated.  
3. A visit schedule based on enrollment date is displayed for printing.  
4. Immediately after randomization , the 5 ml blood sample will be shipped priority 
overnight for early morning arrival at the Biomarker Laboratory of the Icahn School of 
Medicine at Mount Sinai  for biomarker analysis . 
If a connection is interrupted during a randomization session, the process is completely canceled 
and logged.  A backup manual registration and randomization system will also be available to 
provide for short -term sys tem failure or unavailability.  
 
4.2.1.  Treatment  
Treatment should be initiated as soon as possible after randomization.  A maximum of 24 hours 
is allowable.   
 
As per section 2.5.2, the patient’s Ann Arbor results will be provided to the treating physician 
within  48-72 hours of study enrollment/randomization. Patients with AA1/2 status will continue 
on their randomized therapy. In contrast, patients with AA3 status and patients with missing 
biomarker results may continue on the randomized therapy, or another thera py per individual 
treating physician discretion . 
 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-2 4.3. Study Monitoring  
 
4.3.1.  Follow -up Schedule  
The Follow -up Schedule for scheduled study visits is outlined in Table 4. 3. A detailed 
description of each of the forms and the procedures required for forms completion and 
submission can be found in the Data Management Handbook and User’s Guide.  
 
Follow -up Assessments : The timing of follow -up visits is based on the date of randomi zation.  
Following randomization, the Transplant Center can print a Patient Visit Schedule listing target 
dates for assessments.  Weeks 1 -8 visits are primarily for acute GVHD scoring.  The subsequent 
visits are for follow -up reports.  
 
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-3 Table 4.3  
 FOLLOW -UP SCHEDULE  
 
Assessment Time  Target Day1 
(Days Post -Enrollment)  
1 week  7 days  
2 weeks  14 days  
3 weeks  21 days  
4 weeks  28 days  
5 weeks  35 days  
6 weeks  42 days  
7 weeks  49 days  
8 weeks  56 days  
90 days  90 days  
6 months  180 days  
12 months  365 days  
1Target day range = 3 days for Day 7 (subsequent 
visits through Day 56 must be scheduled weekl y and 
within 3 days  of target date ). Target day range 14 
days for  Day 90 and 6 months; and 28 days for  12 
months.  
Criteria for Forms Submission :  
All data for patients are recorded in the electronic Case Report Forms (eCRF) exclusively 
designed for the study.  The Principal Investigator at e ach of the participating center s is 
responsible for complete, accurate and timely reporting of data.  
 
Criteria for timeliness of submission for all study forms are detailed in the Data Management 
Handbook and User’s Guide.  Forms that are not entered into AdvantageEDC within the 
specified time will be considered delinquent.  A missing form will continue to be requested  
either until the form is entered into the AdvantageEDC and integrated into the Data and 
Coordinating Center’s (DCC) master database, or until an exception is granted and entered into 
the Missing Form Exception File, as detailed in the Data Management Hand book.  
 
Corrections in the eCRF are to be conducted only by authorized personnel and may require 
authorization prior to implementation  of corrections. However, all earlier entries  are retrievable 
despite corrections.  All corrections are recorded automatica lly concerning date, time point and 
person. Plausibility and completeness of the eCRF are verified by  personnel at the Data 
Coordinat ing Center.   
 
At all times, the Principal  Investigators at the p articipating centers have full responsibility for 
ensuring  accuracy and authenticity of all clinical and laboratory data entered on the eCRFs.  
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-4 Reporting Patient Deaths:  The Recipient Death Information must  be entered into the web -
based data entry system within 24 hours of knowledge of a patient’s death.  If the cause of death 
is unknown at that time, it need not be recorded at that time.  However, once the cause of death is 
determined, the form must be updated.  
 
Center for International Blood and Marrow Transplant Research (CIBMTR) Data 
Reporting:  Centers partici pating in BMT CTN trials must register pre and post -transplant 
outcomes on all consecutive hematopoietic stem cell transplants done at their institution during 
their time of participation to the Center for International Blood and Marrow Transplant Research  
(CIBMTR).  Registration is done using procedures and forms of the Stem Cell Transplant 
Outcomes Database (SCTOD).  (Note: Federal legislation requires submission of these forms for 
all US allotransplant recipients.)  Additionally, CIBMTR pre - and post - transplant Report Forms 
must also be submitted for all patients enrolled on this trial according to the randomization 
assigned to the patient at the time of initial registration with the CIBMTR.  Long-term follow -up 
of patients on this study will continue th rough routine CIBMTR mechanisms . 
 
4.4. Assessments  
 
All assessments are considered standard -of-care unless identified below by “*.”  
 
Prior to Enrollment/ Randomization  
 The following pre -enrollment/ randomization assessments must be completed within the 
designated timeframe listed below.  
 
1. Protocol -required 5 ml of blood (red top for serum) for the determination of biomarker 
risk status collected immediately prior to enrollment/ randomization .   
2. Complete acute GVHD staging and grading information including assessments of rash, 
diarrhea, nausea/vomiting, weight and liver function tests; Biopsy (if done) of involved 
tissue (standard of care, not research)  within 24 hours  prior to enrollment . 
3. Recording of all systemic immune suppressive therapy (as appropriate:  tacrolimus, 
cyclosporine , etc. ), as well as topical agents  within 24 hours  prior to enrollment . 
4. History and physical exam including height and weight, patient/disease/transplantation 
baseline variables  within 7 days  prior to enrollment.  
5. CBC with differential, platelet count  within 7 days  prior to enrollment.  
6. Liver function tests (bilirubin, alkaline phosphatase, AST, ALT) plus creatinine  within 7 
days prior to enrollment.  
7. Pregnancy test  per institutional practice  (if applicable) within 30 days  prior to enrollment.  
The 5 ml blood sample for biomarker analysis must be shipped as soon as possible  after 
randomization  to the Biomarker Laboratory of  the Icahn School of Medicine at Mount 
Sinai  (see Appendix B). 
 
Prior to Initiation of  Study Therapy   
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-5 Baseline  assessments must be completed within 48 hours prior  to initiation of study therapy 
unless otherwise indicated . 
1. Karnofsky or Lansky Performance Status  
2. Toxicity assessment  
3. Baseline patient -reported outcome measures (M.D. Anderson Symptom Inventory, 
FACT -BMT, SF -36, or PedsQL (Pediatrics)*  Only English  speaking adult and pediatric 
patients,  and Spanish speaking adult patients are eligible to participate in the Health 
Quality of Life ( HQL ) component of this trial.  Patients >18 years will complete the 
FACT -BMT, MOS SF -36 and MDASI instruments . Patients > 8 years through 18 years 
will complete the PedsQL™ Stem Cell Transplant Module.  
4. OPTIONAL 40 mL blood sample for research laboratory studies (see Appendix B) * 
Patients wi th weight < 13 kg will have 3 mL/kg collected.  
 
Baseline assessments required to be done  as close to enrollment  (day 0)  as possible  
1. Baseline myopathy assessments*  (may be done  up to 96 hours after enrollment ) 
a. Hip Flexor and Quadriceps Strength via handheld dynamometer  
b. Two Minute Walk Test  
c. 5-time Sit -to-Stand  
d. Adult Myopathy Assessment Tool (AMAT)  
 
2. Fasting lipid profile  (may be done up to 96 hours after  enrollment ) 
 
Post-Randomization  
The following post -randomization assessments are required of all patients, regardless of  therapy  
received . 
1. Karnofsky or Lansky performance status at Days 56, 90, 180 and 365  
2. Complete acute GVHD  staging and grading information including assessments of rash, 
diarrhea, nausea/vomiting, weight and liver function tests weekly through  Day 56 ; Day 
90, 6 and 12 months  
3. Chronic GVHD  evaluation (if present) Day 28, 56, 90, and 6 and 12 months  
4. CBC with differential, chemistry (including liver function tests) weekly through Day 56; 
Day 90 , 6, and 12 months  
5. Fasting lipid profile at Day 28, 56, and 6 months  
6. Toxicity evaluation weekly through Day 56; Day 90, 6 months and 12 months  
7. Recording of all systemic immune suppression, including steroid dose and drug levels (as 
appropriate for sirolimus, cyclosporine, tacrolimus) weekly through Day 56, Day 90 , 6, 
and 12 months. Second -line immune suppressive therapy (therapy beyond initial 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-6 randomized therapy of either sirolimus or prednisone) should be recorded at each of these 
time points.  
8. Use of topical (skin, GI) steroid agents weekly through Day 56; Day 90 , 6 and 12 
months.  
9. Data on s ystemic infections, and EBV PTLD (or EBV requiring therapy) , recorded as p er 
the BMT CTN (Technical) MOP  through 12 months.  
10. EBV & CMV monitoring as per institutional practice.  
11. Myopathy assessments at Day 56 and 6 months.*  
a. Hip Flexor and Quadriceps Strength via handheld dynamometer  
b. Two Minute Walk Test  
c. 5-time Sit -to-Stand  
d. Adult M yopathy Assessment Tool (AMAT)  
12. Patient reported outcomes (M.D. Anderson Symptom Inventory, FACT -BMT, SF -36, or 
PedsQL (Pediatrics)) at Day 56, 6 months  and 1 year. * Only English  speaking adult and 
pediatric patients,  and Spanish speaking adult patients are eligible to participate in the 
Health Quality of Life ( HQL ) component of this trial.  Patients >18 years will complete 
the FACT -BMT, MOS SF -36 and MDASI instruments. Patients > 8 years through 18 
years will complete the PedsQL™ Stem Cell Trans plant Module.  
13. OPTIONAL 30-40 mL blood s amples for research laboratory studies at Day 7, 28, and 56 
(see Appendix B).* Patients with weight <13 kg will have ≤3 mL/kg collected  at each 
individual time point . 
 
Blood and Marrow Transplant Clinical Trials Network         Sirolimus vs . Prednisone – Protocol 1501  
  Version 2.0 dated July 7 , 2017  
 
 
4-7 Table 4 .4 – REQUIRED ASSESSMENTS  
 Pre- 
Randomize  Pre- 
Therapy  Days Post Randomization  
 Baseline  7* 14* 21* 28* 35* 42* 49* 56 *  90**  180***  365***  
History and physical exam  X             
Pregnancy test (if applicable)  X             
Karnofsky/Lansky performance status   X        X X X X 
Acute GVHD evaluation  X  X X X X X X X X X X X 
Chronic GVHD evaluation       X    X X X X 
CBC with differential, platelet count  X  X X X X X X X X X X X 
Basic chemistry (creatinine)  X  X X X X X X X- X X X X 
Liver function tests (alkaline phosphatase, bilirubin, AST, ALT)  X  X X X X X X X X X X X 
Fasting lipid profile   X1    X    X  X  
Toxicity and AE evaluation   X X X X X X X X X X X X 
Recording of all systemic immune suppression, including steroid dose  X  X X X X X X X X X X X 
Drug level monitoring (e.g. tacrolimus, cyclosporine)  X X X X X X X X X X X X X 
Use of second -line immune suppressive therapy    X X X X X X X X X X X 
Use of topical agents  X  X X X X X X X X X X X 
Malignancy relapse, death    X X X X X X X X X X X 
Systemic infections  X  X X X X X X X X X X X 
EBV PTLD, or EBV requiring therapy    X X X X X X X X X X X 
CMV reactivation requiring therapy    X X X X X X X X    
Myopathy assessments   X2        X  X  
Patient -reported outcomes: MDASI, FACT -BMT, MOS SF-36, PedsQL3  X        X  X X 
REQUIRED 5 mL blood sample for Ann Arbor Panel Scoring  collection  X4             
OPTIONAL Research blood samples for ancillary studies (see Appendix 
B)5  X X   X    X    
*      +/- 3 days to allow for scheduling flexibility, holidays, etc.  Subsequent visits through Day 56 must be scheduled weekly.  
**    +/ - 14 days to allow for scheduling flexibility  
***  +/ - 28 days to allow for scheduling flexibility  
1   The fasting lipid panel  may be done up to 96 hours  after enrollment.  
2      Myopathy assessments may be done up to 96 hours after enrollment.  
3   Only English speaking adult and pediatric patients, and Spanish speaking adult patients are eligible to participate in the He alth Quality of Life (HQL) component of this trial.  Patients >18 years 
will complete the FACT -BMT, MOS SF -36 and MDASI instruments . Patients > 8 years through 18 years will complete the PedsQL™ Stem Cell Transplant Module.  
4    Required blood sample for Ann Arbor Scoring must  be collected prior to enrollment/randomization and shipped overnight immediately afterwards . 
5    Patients with weight < 13 kg will have ≤3 mL/kg collected   
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-8  
4.5. Weekly GVHD Monitoring  
 
GVHD scoring will be pe rformed weekly for 8 weeks from study entry.  Days 0, 28 and 56 ( +3 
days) scoring must be performed by direct observation at the Transplant Center.  Evaluations at 
other time points may be performed by competent clinicians other than at the Transplant Cent er 
but Transplant Center is responsible for collecting all required data.  
 
4.6. Adverse Event Reporting  
 
Adverse Event : An adverse event  (AE) is any undesirable  sign, symptom or medical condition 
or experience that develops or worsens in severity after starting the first dose of study treatment 
or any procedure specified in the protocol, even if the event  is not considered to be related to the 
study.   
 
Expectedness : An adverse event can be Expected or Unexpected  
• Expected adverse events  are those that have been previously identified as resulting from 
administration of the agent. For the purposes of this study, an adverse event is considered 
expected  when it appears in the current adverse event list, the Investigator’s Brochure, 
the package insert or is included in the informed consent document as a potential risk.  
• Unexpected adverse events  are those that vary in nature, intensity or frequency from 
information in the current adverse event l ist, the Investigator’s Brochure, the package 
insert, or when it is not included in the informed consent document as a potential risk.  
 
Serious Adverse Event:  A serious adverse event (SAE) , as defined by  21 CFR 312.32 , is any 
adverse event that results in one of the following outcomes, regardless of causality and 
expectedness:  
• Results in death  
• Is life -threatening.  Life-threatening means that the person was at immediate risk of 
death from the reaction as it occurred, i.e., it does not include a reaction whi ch 
hypothetically might have caused death had it occurred in a more severe form.  
• Requires or prolongs inpatient hospitalization  (i.e., the event required at least a 24 -
hour hospitalization or prolonged a hospitalization beyond the expected length of stay).  
Hospitalization admissions and/or surgical operations scheduled to occur during the study 
period, but planned prior to study entry are not considered SAEs if the illness or disease 
existed before the person was enrolled in the trial, provided that it did not deteriorate in 
an unexpected manner during the trial (e.g., surgery performed earlier than planned).  
• Results in persistent or significant disability/incapacity.  Disability is defined as a 
substantial disruption of a person’s ability to conduct normal l ife functions.  
• Is a congenital anomaly or birth defect;  or 
• Is an important medical event  when, based upon appropriate medical judgment, it may 
jeopardize the participant and require medical or surgical intervention to prevent one of 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
4-9 the outcomes listed above. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home; blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of d rug dependency or drug abuse.  
 
Medical and scientific judgment should be exercised in deciding whether expected reporting is 
also appropriate in situations other than those listed above.  For example, important medical 
events may not be immediately life th reatening or result in death or hospitalization but may 
jeopardize the subject or may require intervention to prevent one of the outcomes listed in the 
definition above (e .g., suspected transmission of an infectious agent by a medicinal product is 
consider ed a Serious Adverse Event). Any event is considered a Serious Adverse Event if it is 
associated with clinical signs or symptoms judged by the investigator to have a significant 
clinical impact.  
 
4.6.1.  Required Adverse Event Reporting  
Adverse event reporting  will be consistent with BMT CTN procedures (BMT CTN 
Administrative Manual of Procedures, Chapter 6) . It is BMT CTN policy that AEs must be 
reported even if the investigator is unsure whether a relationship exists between the adverse 
event and the use of study  treatment.  Unexpected, serious  adverse events ( SAEs) will be 
reported through an expedited AE reporting system via AdvantageEDC.  Unexpected, life-
threatening and fatal SAEs  must be reported within 24 hours of knowledge of the event.  All 
other un expecte d SAEs  must be reported within three business days of knowledge of the event.  
Events entered in AdvantageEDC  will be reported using NCI’s Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0.  Expected AEs will be reported using NCI’s Common  
Terminology Criteria for Adverse Events (CTCAE) Version 4.0 at regular intervals as defined on 
the Form Submission Schedule.  Any expected life -threatening SAE not collected on another 
study form must be reported through the expedited AE reporting system v ia AdvantageEDC . 
 
The Data and Safety Monitoring Board will receive  summary reports of all unexpected  SAEs  on 
a semi -annual basis.  
 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-1 CHAPTER 5  
 
 
5. STATISTICAL CORRELATIONS  
 
5.1. Study Design  
 
The study is designed as a Phase II randomized, open label, multicenter trial to identify whether 
sirolimus is a potential alternative to prednisone as an up -front treatment for patients with 
standard risk acute GVHD (defined by both refined Minnesota standard clinical risk and AA1/2 
biomarker risk group).  The hypothesis is that sirolimus will produce comparable response rates 
while also reducing steroid burden in this population.  As this is t he first trial prospectively 
assessing sirolimus in a multicenter setting, the trial is not designed to formally declare non -
inferiority but rather to estimate the difference in response rates between the sirolimus arm and 
the prednisone (or standard of ca re) arm. Estimation of this difference along with establishing 
more precise estimates for a key secondary endpoint with a response definition incorporating a 
measure of steroid burden (requirement a patient is on less than 0.25 mg/kg at Day 28) will allow 
assessment of sirolimus as a potential upfront treatment for GVHD response.  
 
Patients will be randomized to either sirolimus or prednisone.  The primary endpoint is complete 
or partial response  (relative to their GVHD status on the day of randomization) on Day 28 post -
randomization  with secondary endpoints assessing alternate definitions of efficacy , safety , 
steroid burden and quality of life. The target enrollment is 120 eligible, randomized AA1/2 
patients. One hundred and fifty patients are expected to be randomized as approximately 20% of 
randomized patients will have AA3 status results  or missing biomarker results  and be removed 
from the primary analysis (see the Primary Endpoint Section for details).  
 
5.1.1.  Accrual  
It is estimated that accrual will take 2 y ears. 
 
5.1.2.  Randomization  
Randomization will be performed in a 1:1 ratio using random block sizes for the two arms and 
stratified by transplant center.   
 
5.1.3.  Primary Endpoint  
The primary endpoint of the study is defined in Chapter 3. Briefly, the primary endpoint is 
complete or partial response  of acute GVHD (as compared to status at day of randomization) on 
Day 28 post -randomization. Note that patients classified as AA3 per th e biomarker criteria and 
patients with missing biomarker results will be excluded from the primary analysis (i.e. primary 
and secondary endpoints) population and described in a secondary analysis.  
 
5.1.4.  Primary Hypothesis  
The primary hypothesis is that up front  treatment with sirolimus will result in comparable CR/PR 
rates as up front treatment with prednisone. No formal hypothesis testing will take place. Instead 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-2 the difference in response rates between the two arms will be estimated with a 90% confidence 
interval.  
 
5.1.5.  Sample Size and Power Considerations  
The primary endpoint is CR/PR at Day 28 post -randomization. Background data on treatment 
with sirolimus is available for 27 standard risk (Minnesota Criteria) patients. The overall CR/PR 
rate in the population wa s 88.9% (95% CI 77.0%, 100.0%). If patients receiving any level of 
prednisone are considered failures (per Chapter 3) then the observed CR/PR rate was 55.6% 
(95% CI 36.8% -74.3%). Considering background data from BMT CTN 0802, data were 
available for 95 pla cebo treated patients meeting the standard risk criteria at GVHD onset. The 
response  rate in that population was 64.2% (95% CI 54.6% -73.9%). Note that PR was no t 
formally adjudicated by the Endpoint Review Committee for BMT CTN 0802 . Instead a 
response of  Better Grade  (compared to grade at diagnosis) was adjudicated and considered here 
as a surrogate for PR . While the point estimates differ slightly, the confidence intervals for the 
two populations are overlapping. Table 5.1 shows the lower bound of a 90% a symptotic 
confidence interval given  two scenarios: 1) success rate of 60% in each arm and 2) success rate 
of 60% in the prednisone arm and 50% in the sirolimus arm  (sirolimus response rate is 10% 
lower) . 
Table 5.1: Lower Bound of Asymptotic 90% Confidence Interval For Difference in 
Response Rates Between Sirolimus and Prednisone Arms Assuming Equal Rates (60%) 
and a 10% Lower Response Rate in the Sirolimus Arm With a 20% Inflation Due To 
Biomarker Results  
Randomized  Analyzed  N Analyzed Per 
Arm Lower Bound o f 
90% Confidence 
Interval Assuming 
No Difference  
Between 
Treatment Arms * Lower Bound of 
90% Confidence 
Interval Assuming 
Sirolimus  
Response Rate is  
10% Lower * 
125 100 50 -16% -26% 
150 120 60 -15% -25% 
175 140 70 -14% -24% 
200 160 80 -13% -23% 
225 180 90 -12% -22% 
250 200 100 -12% -22% 
* Difference calculated as Sirolimus response rate minus Prednisone response rate.  
 
The number randomized assumes that 20% of randomized patients will have biomarker results 
indicating high risk disease (AA3) or missing  biomarker results. Note that 60 analyzable patients 
per arm (150 randomized) will result in a lower bound of 15% assuming that the success rates in 
the two populations are equivalent. If sirolimus is 10% worse than the prednisone arm, the lower 
bound of t he confidence interval will exceed 15%.  Difference in Day 28 CR/PR rate across the 
two arms will be reported with associated 90% confidence interval, however no pre -planned 
difference or width of confidence interval will be used to indicate failure of either arm or serve 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-3 as a requirement for consideration of seconda ry endpoints  (i.e. formal non -inferiority will not be 
declared in this trial) . A key secondary endpoint is the proportion of patients in CR/PR with a 
steroid dose of ≤0.25 mg/kg by Day 28. Of the 95 placebo patients, 22.1% (95% CI 13.8% - 
30.5%) achieved a  CR/PR by Day 28 and were receiving ≤0.25 mg/kg. This estimate may not be 
reliable, however, as the taper for BMT CTN 0802 suggested a minimum of 0.25 mg/kg on Day 
28 as such this may be an underestimate of the true rate. Using the upper end of the confide nce 
interval, sixty patients per arm would provide 80.6% power ( two-sided 5% type 1 error rate) to 
test for a difference of 25% between the two groups (30% Prednisone vs . 55% Sirolimus).  
 
5.2. Interim Analysis and Stopping Guidelines  
 
5.2.1.  Interim Analysis  
There wil l be no interim analyses for efficacy or futility as this is a small phase II study.  
 
5.2.2.  Guidelines for Safety Monitoring  
Monitoring of two key safety endpoint s will be conducted monthly, and if rates significantly 
exceed pre -set thresholds, the NHLBI will be  notified in order that the DSMB can be advised.  
Policies and composition of the DSMB are described in the BMT CTN's Manual of Procedures.  
The stopping guideline s serve as trigger for consultation with the DSMB for additional review.  
The key safety endpo ints for this study are: 1)  failure of sirolimus therapy with a failure for the 
stopping rule defined as the addition of a systemic immune suppressive therapy beyond 
prednisone among those patients or iginally treated with sirolimus and 2) overall mortality . Both 
of these endpoints will be monitored among AA1/2 patients only ; failure of sirolimus therapy 
will be monitored in the sirolimus arm only.  
 
5.2.2.1 Day 42 Failure of Sirolimus Therapy  
 
The rate of sirolimus failure will be monitored up to 42 days post -randomization.  At least three 
events must be observed in order to trigger review.  The expected probability of 42 day sirolimus 
failure is approximately 25 -30% (estimate derived from primary sirolimus monotherapy data, as 
well as anticipated rat e of secondary therapy use beyond prednisone in prior BMT CTN aGVHD 
therapy trials).11,12  Each month, the null hypothesis that the 42-day sirolimus failure rate is less 
than or equal to 25% is tested.  For this rule, a bin omial  sequential probability ratio test (SPRT) 
will be implemented.  
 
This sequential testing procedure conserves type I error at 5% across all of the monthly 
examinations for the sirolimus arm .  The SPRT can be represented graphically.  At each monthly 
interim analysis, the number of evaluable patients on study is plotted against the total number of 
treatment failures .  The continuation region of the SPRT is defined by two parallel lines.  Only 
the upper boundary will be used for monitoring to protect against excessive 42-day sirolimus 
failure.  If the graph crosses the upper boundary , the SPRT rejects the null hypothesis, and 
concludes that there are more events than predicted by the number of evaluable patients  on study.  
Otherwise, the SPRT continues until enrollment is complete . Only failures that occur on or 
before the patient has been followed for 42 days are counted.   
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-4 The boundaries for the binary  SPRT were constructed by setting the null rate of sirolimus failure 
to be  25% versus an alternative of 50% for 42 -day sirolimus fa ilure. To construct the boundary, 
the nominal type I and type II errors were set to be 10% and 5% respectively. The upper 
boundary  is defined by a  slope of 0.36907  and a n upper  intercept of 2.04921.  Since the upper 
boundary alone is being used, the actual type I error of the binomial SPRT will be less than the 
nominal value without a substantial  increase in type II error for the alternatives of interest (i.e. 
sirolimus therapy failure rates higher than expected). Table 5.2.1 illustrates the number of 
observ ed events required to cross the boundary for the binomial SPRT.  
TABLE 5.2 .1:  Safety Monitoring Guidelines for Failure of Sirolimus Therapy  
Number Evaluable Patients  Number of Events  On or Prior to Day 42  
4-5 4 
6-7 5 
8-10 6 
11-13 7 
14-16 8 
17-18 9 
19-21 10 
22-24 11 
25-26 12 
27-29 13 
30-32 14 
33-35 15 
36-37 16 
38-40 17 
41-43 18 
44-45 19 
46-48 20 
49-51 21 
52-54 22 
55-56 23 
57-59 24 
60 25 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-5 5.2.2.2 Day 56 Overall Mortality  
 
Day 56 overall mortality is the second key safety endpoint. This endpoint will be monitored 
within each treatment  arm using an extension of the (SPRT) for censored exponential data, as 
described in greater detail below and in Appendix D. In brief, unlike t he binary SPRT which 
assesses the event rate in the number of evaluable patients, the censored exponential SPRT 
considers the number of events relative to the total at risk time observed on study. The SPRT is 
represented graphically with the number of even ts on the y -axis and the total at risk time on the 
x-axis. The upper boundary of the SPRT will be used to guard against excess mortality. This 
procedure assumes a censored exponential distribution for overall mortality  during the first 56 
days, and censors  follow -up time after 56 days.  
 
Based on background data for standard risk acute GVHD patients, the expected Day 56 overall 
mortality is 13.1%. As this estimate includes AA3 patients in addition to AA1/2 , to be 
conservative, the null for the monitoring bound will be set at 10%. An SPRT contrasting 10% vs 
25% Day 56 overall mortality results in decision boundaries with a common slope of 1.18 and an 
upper intercept of 2.29 based on nominal type 1 and type II errors of 9% and 10% respectively  
with the type I and II errors selected based on the simulation study and t he actual operating 
characteristics of the SPRT shown in Table 5.2.2 that assum ed uniform accrual of 60 individuals 
over a 24 month time period, and exponential time to failure after randomization .   
 
TABLE 5.2 .2:  OPERATING CHARACTERISTICS OF SEQUENTIAL TESTING 
PROCEDURE FROM A SIMULATION STUDY WITH 10,000 REPLICATIONS  
Day 56 Overall Mortality  
True 56-Day Rate  10% 15% 20% 25% 
Probability Reject Null  0.053 0.281 0.641 0.888  
Mean Month Stopped  25.2 22.1 16.8 12.0 
Mean # Endpoints in 56  Days  5.8 7.6 7.9 7.0 
Mean # Patients Enrolled  58.2 51.6 40.4 29.6 
 
If the true Day 56 overall mortality rate is in line with the expected rate (i.e. 10%), then the 
stopping guideline has a 5% probability of being triggered. If the true overall mortality rate is 
higher than expected (i.e. 25% by Day 56), then the stopping guideline has an 89% probability of 
being triggered (on average 12 months after opening when 30 patients have been enrolled).  
 
No monitoring  of secondary therapy delivered beyond prednisone will be performed in the 
prednisone arm, as this treatment is considered standard of care. We will prospectively monitor 
the rate of AA3 participants which is expected to be 20% of standard risk patients. T his rate will 
be reported (with a 95% confidence interval) to the DSMB at each semiannual meeting to 
determine if the rate is higher than expected.  
5.2.3.  Demographic and Baseline Characteristics  
Demographics and baseline characteristics will be summarized for al l patients.  Characteristics to 
be examined are: age, gender, race/ethnicity, performance status, primary disease, risk status, 
transplant conditioning therapy characteristics, donor type and HLA mismatch, graft source, 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-6 initial GVHD prophylaxis delivered, donor and recipient CMV status, acute GVHD organ 
staging and overall grade at enrollment, topical steroid therapy use.  Between group comparisons 
will be performed for continuous variables via a t -test (or Wilcoxon Rank -Sum) and for 
categorical variables, via the chi -square test (or Fisher’s Exact as appropriate).  
 
5.2.4.  Analysis of Primary Endpoint  
The difference in Day 28 CR/PR rates between arms will be estimated along with a 90% 
confidence interval. Note that patients classified as high risk per biomarker results and patients 
with missing biomarker results will be excluded from the primary analysi s. In addition to the 
difference in rates, within arm CR/PR rates will be estimated with accompanying confidence 
intervals.   
 
5.2.5.  Analysis of Secondary Endpoints  
Given the large number of secondary endpoints, a significance level of 5% will be used for all 
comparisons (and 95% confidence intervals). This provides some control of multiplicity without 
overly restricting the study’s ability to detect differences.  
 
1. Proportion of Patients with CR/PR and Steroid Dose 0.25 mg/kg or less  
This is a key secondary endpoi nt of the trial. The rates will be estimated within each arm and 
comparison between arms will occur using the Z test for binomial proportions (or Barnard’s 
Exact Unconditional as appropriate).  
 
2.  Proportion of response  
Proportions of complete, partial (PR),  mixed response, no response and progression  among 
surviving patients  at Day 14, 28 and 56 will be compared between the treatment groups using the 
chi-square test  (or Fisher’s Exact as appropriate).    
 
3.  Treatment Failure  
Proportion of primary treatment fai lures at Days 14, 28 and 56 will be compared using the Z test 
for comparing binomial proportions (or Barnard’s Exact Unconditional test as appropriate).  
4. Incidence of Chronic GVHD  
Cumulative incidence of chronic GVHD will be estimated (treating death and re lapse as a 
competing risk) and curves will be compared using Gray’s test. Estimates and confidence 
intervals will be provided for 6 and 12 months post -randomization.  
 
5.  Incidence of Systemic Infections  
Frequencies of infections will be tabulated by site of disease, date of onset, and severity.  The 
time to first serious infection will be described using the cumulative incidence function with 
death as the competing risk, and compared between treatments using Gray’s test.  
 
6.  Event -Free Survival  
Event -free survi val within each treatment group will be estimated using Kaplan -Meier 
methodology with event time being the earliest time a patient met one of the various criteria for 
failure or time of last follow -up for those patients not meeting the failure criteria. Pr e-specified 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-7 time points of interest are 6 and 12 months post -randomization. Estimates and confidence 
intervals will be calculated for these time points.  
 
7. Overall Survival  
Overall survival will be estimated using Kaplan -Meier methodology with event time be ing the 
earliest time of death or last follow -up. Pre -specified time points of interest are 6 and 12 months 
post-randomization. Estimates and  confidence intervals will be calculated for these timepoints.  
 
8.  Disease -Free Survival  
Disease -free survival will be estimated using Kaplan -Meier methodology with event time being 
the earliest time a patient experienced a relapse of underlying malignancy, death or last follow -
up. Pre -specified time points of interest are 6 and 12 months post -randomization. Estimates a nd  
confidence intervals will be calculated for these time points.  
 
9.  GVHD -Free Survival  
The proportion of patients alive and GVHD free at 6 and 12 months post -randomization will be 
estimated and compared between treatment groups using the Z test for compar ing binomial 
proportions (or Barnard’s Exact Unconditional test as appropriate).  
 
10.  Non-relapse Mortality  
Cumulative incidence of non -relapse mortality will be estimated (treating relapse as a competing 
risk) and curves will be compared using Gray’s test. E stimates and confidence intervals will be 
provided for 6 and 12 months post -randomization.  
 
5.2.6.  Analysis of Explorato ry Endpoints  
The following endpoints and subgroup analyses are considered exploratory and will be analyzed 
at a significance level similar to the secondary endpoints.  
 
1. Steroid Dose  
Cumulative steroid dose will be  described and  compared between the treatment groups using a 
Wilcoxon Rank Sum test.  
 
2.  Topical Therapy  
The proportion of patients using either topical skin or topical GI steroids will be  estimated within 
treatment group and by use at randomization. Among patients entering with no history of topical 
therapy, the proportion of patients initiating new topical treatment will be compared between 
treatment groups using the Z test for comparing binomial proportions (or Barnard’s Exact 
Unconditional test as appropriate).  
 
3. Discontinuation of Immune Suppression  
Cumulative incidence of immune suppression discontinuation will be estimated (treating death as 
a competing risk) and curves will be compare d using Gray’s test. Estimates and confidence 
intervals will be provided for  Day 56,  6 and 12 months post -randomization.  
 
4. Incidence of EBV -associated lymphoproliferative disorder  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-8 The incidence of EBV -associated lymphoproliferative disorder or EBV reactivat ion therapy will 
be described using the cumulative incidence function, treating death as the competing risk.  
Cumulative incidence curves will be compared between treatments using Gray’s test.  
 
5. Incidence of hyperglycemia  
Incidence of hyperglycemia and use of diabetes therapy at baseline, Day 28 and Day 56 will be 
estimated and compared between arms using a Z-test (or Barnard’s Exact Unconditional as 
appropriate).  
 
6.  Functional Myopathy  
Change from baseline in functional myopathy score at Day 56 and 6 -months post-randomization.  
i. Hip Flexor and Quadriceps Strength via handheld dynamometer  
ii. Two Minute Walk Test  
iii. 5-time Sit -to-Stand  
iv. Adult Myopathy Assessment Tool (AMAT)  
These measures will first be assessed in patients with available data. Change from baseline 
within treatment group will be assessed using a Wilcoxon Signed Rank test at each timepoint. 
Change from baseline at each timepoint will be compared between treatme nt groups using a 
Wilcoxon Rank Sum test.  
 
7.  Hyperlipidemia  
Prevalence of hyperlipidemia as measured by fasting lipid panel and use of lipid -lowering agents 
at baseline, Days 28, 56 and 180 post -randomization will be compared between groups at each 
timepoi nt using a Z -test for binomial proportions (or Barnard’s Exact Unconditional test as 
appropriate).  
 
8.  Post-transplant thrombotic microangiopathy  
Cumulative incidence of post -transplant thrombotic microangiopathy will be estimated (treating 
death as a compet ing risk) and curves will be compared using Gray’s test. Estimates and 
confidence intervals will be provided for 6 months post -randomization.  
 
9.  CMV -reactivation  
Proportion of patients requiring therapy for CMV -reactivation by Day 56 post -randomization  
will be compared between treatment groups using a Z -test (or Barnard’s Exact unconditional as 
appropriate).  
 
10.  Change in Patient -Reported Outcomes from Enrollment to Day 56 , 6 months  and 1 year . 
Participant self -reported measures will be assessed using the MDAS I, FACT -BMT, and MOS 
SF-36 (or PedsQL for Pediatric patients) at enrollment, day 56, 6 months and 1 year.  These will 
be scored according to the recommendations of the developers.  Patient reported outcomes  at 
each time point will be summarized using simpl e descriptive statistics (mean, SD).  PRO among 
survivors at each time point will be compared between treatment arms in an initial analysis using 
two sample t -statistics.  The missing data pattern of the PRO measurements will be examined 
using graphical te chniques and logistic regression models conditional on survival.  At each time 
point, estimates of the difference in PRO between the treatments conditional on survival at that 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
5-9 time point will be obtained using inverse probability of censoring weighting wit h independent 
estimating equations to account for missing data.  
 
5.2.7.  Secondary Analysis of AA3 Patients:  
A secondary analysis will consider study outcomes for AA3 patients (note patients with missing 
biomarker results will be excluded). Roughly 30 AA3 patients are expected to be enrolled with 
15 receiving sirolimus while awaiting results and 15 receiving prednisone. Outcomes for these 
patients will be described by initial treatment to assess whether up front sirolimus vs. prednisone 
impacted outcome. Du e to small numbers, the analysis will be primarily descriptive as we are not 
likely to have power to detect differences between the groups.  
 
5.2.8.  Exploratory Subgroup Analysis:  
Rates of Day 28 CR/PR (and 95% confidence intervals) will be estimated for each trea tment 
group by donor type, graft source, and HLA mismatch (matched vs . mismatched). As the 
numbers for these subgroup analyses will be small, the intent is not to formally declare 
differences between subgroups, but rather to identify the potential for diff erences that may need 
to be accounted for in future trials.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
A-1 APPENDIX A  
 
HUMAN SUBJECTS  
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
A-2 APPENDIX A  
 
HUMAN SUBJECTS  
 
 
Subject consent : The Network will provide template s of the consent and assent form s to each 
center.  Each center will customize the template s according to their local requirements and 
submit for review  by the DCC for adequacy prior to submitting to the local Internal Review 
Board (IRB)  or the NMDP IRB  of Record .  Each center must provide evidence of IRB approval  
of the protocol and consent/assent forms .  
 
Candidates for the study will be identified as described in Chapter 4 of the protocol.  The 
Principal Investigator or his/her designee at each transplant center will contact the candidates , 
provide the patient with information about the purpose of the study and obtain consent . A trained  
person will enroll/randomize the patient in the AdvantageEDC system.  
 
Confidentiality : Confidentiality will be maintained by individual names being masked and 
assigned a patient identifier code.  The code relaying the patient’s identity with the ID code will 
be kept separately at the center.  The ID code will be transmitted to the network.   
 
Participation of women, children,  minorities and other populations : Women, children and 
ethnic minorities will be included in this study.  
 
Accrual will be monitored within each center with the expectation that the enrolled patient 
population is representative of the transplanted patient p opulation at each center.  Representation 
will be examined by comparing gender, race, ethnicity and age distributions.  Accrual of 
minority patients will be expected to be in proportion to the number of minority patients 
transplanted at each center.  The D CC and NHLBI will discuss enrollment anomalies with the 
centers.  
 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
Information & Informed Consent Form   Initials   
B-3  
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX B  
 
LABORATORY PROCEDURES  
 
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
Information & Informed Consent Form   Initials   
B-4 APPENDIX B  
 
LABORATORY PROCEDURES  
 
 
A. Blood Samples for Protocol -required GVHD Risk Assessment – Ann Arbor Biomarker 
Panel Scoring  
 
Once consented, a 5 mL of blood sample (red top for serum) will be collected from the patient 
prior to randomization . The blood sample will be shipped on the day of collection  after 
randomization  by priority overnight FedEx for early morning  arrival at the Biomarker 
Laboratory of the Icahn School of Medicine at Mount Sinai  for biomarker panel analysis. 
Samples can be shipped Monday to Friday each week, and results can be delivered back to 
submitting clinical centers Tuesday through Saturday o f each week.  
 
Once received in the laboratory, the GVHD biomarkers used to assign the Ann Arbor GVHD 
score will be measured by ELISA using standard technical procedures in a CLIA certified 
laboratory. Processing the sample, measuring, and confirming the EL ISA assay results takes 4.5 
hours (range 4 -6 hours). Once the Ann Arbor score is confirmed, the investigator at the 
participating center will be notified if the patient has Ann Arbor 1/2, Ann Arbor 3 or missing 
biomarker risk status  by telephone with email  confirmation . Treating physicians will be notified 
of the patient’s Ann Arbor GVHD score within 72 hours of study enrollment and randomization 
(usually within 48 hours), and will receive a written laboratory report for the patient’s chart 
detailing the fi nal Ann Arbor score assignment based upon the expert review of testing results 
and algorithm output.  
 
GVHD therapy for Ann Arbor 3 patients, which will be at the treating physician’s discretion, 
may be used in exploratory analyses to generate hypotheses fo r future high risk GVHD trials.  
 
B. Optional Research Samples Supporting Future Biomarker Studies  
 
Optional r esearch blood samples will be drawn at baseline (pre -treatment ), and then at the serial 
time points outlined in the table below.  
 
B.1 Rationale for type and schedule of planned optional research samples  
 
1. Optional Baseline samples  
 
Optional Baseline samples will be drawn prior to initiation of randomized therapy. While  
samples for subsequent RNA studies will be collected in PAXgene tu bes (to stabilize RNA), 
other samples will be shipped to the BMT CTN Repository for processing, and aliquot storage.  
 
The major planned use of these optional research samples will be for discovery of new RNA and 
protein biomarkers of therapeutic response and subsequent mortality among standard risk acute 
GVHD patients. Both single time point baseline values and change from baseline to Day 7 values 
will be considered. Studies will be performed separately among sirolimus -treated  or prednisone -
treated patient s, and commonality of predictive markers will be explored. While protein markers 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
Information & Informed Consent Form   Initials   
B-5 of GVHD response and subsequent mortality have been well established in the setting of 
standard prednisone primary therapy, this has not been addressed in sirolimus primary th erapy 
before. Thus, this trial offers a completely new opportunity for discovery. The concurrent 
collection of research blood samples from AA3 patients permits comparisons across the AA1/2 
vs. AA3 patients, both in the setting of sirolimus monotherapy and standard prednisone therapy.  
 
Additional PBMC isolated for immune reconstitution research will at minimum be used for 
establishing baseline pre -treatment levels of regulatory T cells (Treg ). Change from this baseline 
value to subsequent measures (including Days 7, 28, and 56) will be compared across the 
sirolimus - and prednisone -treated patients. We hypothesize that sirolimus therapy will support 
greater percentage and absolute number of Tr eg, as well as Treg/Tconv ratio, over the therapy 
period in comparison to the prednisone -treated group. As well, correlation between Treg and 
Treg/Tconv ratio and GVHD response and subsequent outcomes will be examined.  
 
In addition to these studies, store d samples will be available for use by additional investigators. 
Submitted proposals for use of stored samples will be first reviewed by the protocol team and 
further adjudicated according to the procedures detailed in the BMT CTN MOP.  
 
2. Optional Serial sa mples following initiation of randomized therapy  
 
Sample types and procedures for optional serial follow up samples mirror those outlined for 
baseline samples.  
 
Change from baseline to subsequent samples (e.g. Day 7) will be examined in the predictive 
biomarker analyses outlined above. In particular, change in serum protein biomarkers from 
baseline to Day 7 will be prioritized.  
 
Single time point samples at Day 28 and 56 will also be utilized for studies examining 
association between RNA and protein biomar kers and Day 28 or 56 GVHD response categories 
outlined in the protocol. These interval time point samples (e.g. Day 28, Day 56) can also be 
used for prediction of later outcomes, including development of chronic GVHD, as well as 
development of immune tole rance as measured by freedom from GVHD and complete 
discontinuation of immune suppression. We anticipate that – with an anticipated median onset 
time of acute GVHD of approximately 20 -30 days post -transplant – that the Day 56 sample 
(post -acute GVHD onset)  will largely occur around 90 days post -transplant. This sample will be 
ideal for chronic GVHD predictive analyses, as this should precede median onset time for 
chronic GVHD (expected around 4 -6 months post -HCT). Finally, these later sample time points 
will permit an extended view of Treg reconstitution from therapy initiation onward over a several 
month period. We will compare Treg reconstitution across study arms at both single time points, 
as well as the trajectory from baseline onward.  
 
B.2 Optional Res earch Sample procedures  
All optional research sample aliquots will be given unique bar code designations that cannot be 
linked back to the participant’s name or other identifying information. Laboratory test results, 
clinical information, etc., associated with the coded samples may be provided to the Investigators 
to associate biological findings with clinical outcomes.  Investigators will be able to link results 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
Information & Informed Consent Form   Initials   
B-6 from serial serum sample aliquots (for example: Pre -treatment, Day 7, Day 28 post -treatment 
initiation samples).  Similarly, investigators will be able to link data from different sample types.  
All optional research samples will be collected and shipped same -day (Monday -Friday) to the 
BMT CTN Biorepository for next -day processing (Tuesday -Saturday)  and sample aliquot 
storage. Sample collection and shipping procedures are detailed in the BMT CTN 1501 Research 
Sample Information Guide.  
 
OPTIONAL Research Sample Collection Schedule, Processing and Aliquot Storage  Summary  
Optional Research Samples  (collected from all patients that provided consent for research samples)  
Time Points  Sample 
Quantity1 Stored 
Material  Sample 
Processing 
& Storage 
Site Aliquots Stored  Purpose  
Pre-Treatment 
&  
Post- Initiation of 
Treatment  
Day 28 ± 3 
Day 56 ± 3 10 mL  
PAXgene  Whole 
Blood  
Lysate  BMT CTN 
Biorepository  Maximum  
4 aliquots  
2.5 mL -fill PAXgene tubes; 
stored at -80º C  Gene Expression 
Profile Research  
Pre-Treatment 
&  
Post- Initiation of 
Treatment  
Day 7 ± 3 
Day  28 ± 3 
Day 56 ± 3 20 mL  
Heparin  Viable 
PBMC  BMT CTN 
Biorepository  Maximum  
6 aliquots  
1.0 mL aliquots containing ~ 
2.5-5.0 x 106 PBMC; controlled -
rate frozen and stored in LN2  Immune 
Reconstitution 
Research  
10 mL  
Serum 
Clot Tube  Serum  BMT CTN 
Biorepository  Maximum  
10 aliquots  
~ 0.5 mL aliquots;  
stored at -80º C  Proteomic and 
miRNA Biomarker 
Research  
1  Sample Quantity  Patients with weight < 13 kg will have ≤ 3 mL/kg collected at each individual time point  Research samples 
should be drawn in the following descending order of priority to total per missible volume: (1) 20mL heparin tube for PBMC, (2) 
10mL serum clot tube for serum, and (3) 10mL PAX gene tube for whole blood lysate  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
C-1 APPENDIX C  
 
DIAGNOSIS AND SEVERITY SCORING FOR ACUTE  
AND CHRONIC GVHD  
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
C-2 APPENDIX C  
 
DIAGNOSIS AND SEVERITY SCORING FOR ACUTE AND CHRONIC GVHD  
 
 
1. GVHD organ staging21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
C-3  
2. Grading of Chronic GVHD (NIH Criteria)22 
 
 
Organ scoring of chronic GVHD. ECOG indicates Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; LPS, Lansky 
Performance Status; BSA, body surface area; ADL, activities of daily living; LFTs, liver function tests; AP, alkaline phosphatase; ALT, alanine 
aminotransf erase; ULN, normal upper limit. *Weight loss within 3 months. Skin scoring should use bot h percentage of BSA involved by disease 
signs and the cutaneous features scales. When a discrepancy exists between the percentage of total body surface (BSA) score a nd the skin feature 
score, OR if superficial sclerotic features are present ( Score 2), but there is impaired mobility or ulceration (Score 3), the higher level should be 
used for the final skin scoring. To be completed by specialist or trained medical providers. **Lung scoring should be perform ed using both the 
symptoms and FEV1 scores whenever possible. FEV1 should be used in the final lung scoring where there is discrepancy between symptoms and 
FEV1 scores.  

Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
C-4  
 

Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
C-5  
 
 
 
  

Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
C-6 3. Categories of Acute and Chronic GVHD  
 
 
Categories of Acute and Chronic GVHD  
Category  Time of 
Symptoms 
after HCT  Presence 
of Acute 
GVHD 
Features  Presence of 
Chronic 
GVHD 
Features*  
Acute GVHD  
  Classic acute GVHD  ≤100 d  Yes No 
Late-onset acute  GVHD  >100 d  Yes No 
Chronic GVHD  
  
Classic chronic GVHD  No time 
limit  No Yes 
Overlap syndrome  No time 
limit  Yes Yes 
*As defined in section 4 (below)  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
C-7 
4. Signs and Symptoms of Chronic GVHD22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
D-1 APPENDIX D  
 
DERIVATION OF A SEQUENTIAL TEST STATISTIC  
FOR CENSORED EXPONENTIAL DATA  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
 APPENDIX D  
 
DERIVATION OF A SEQUENTIAL  TEST STATISTIC FOR CENSORED 
EXPONENTIAL DATA  
 
 
Background – The Sequential Probability Ratio Test  
 
Let 
)(.,f be the density function for random variable X.  According to Neyman and Pearson, 
the most powerful test of 
o H:0  versus
1 1: H  decides in favor of 
1H  or 
0H if 
c Ln  or 
c Ln
, respectively, where 
n
ii i n xf xf L );(/);(0 1  is the likelihood ratio, and 
c is 
determined to have the size 
 .  When the sample size is not fixed in advance, further 
improvement is possible by using Wald’s Sequential Probability Ratio Test (SPRT).  The SPRT 
continues to sample as lo ng as 
A LBn  for some constant 
A B1 , stops sampling and 
decides in favor of 
1H as soon as 
A Ln , and stops sampling and decides in favor of 
0H as soon 
as 
B Ln . 
 
The usual measures of performance of such a procedure are the error probabilities 
 and
 of 
rejecting 
0H when 
0 , and of accepting 
0H when 
1 , respectively, and the expected 
sample size 
)( )|( NE NEj j .  Wald and Wolfowitz showed that among all tests, sequential or 
not, for which 
) reject (Pr0 0 H  and 
) reject (Pr0 1 H , and for which 
)(NEj  are finite, j=0,1, 
the SPRT with error probabilities 
  and 
 minimizes 
)(0NE  and 
)(1NE .  If, in addition, the 
,...2,1xx
 are independent and identically distributed (i.i.d.) with density function 
),(xf , with 
monotone likelihood ratio in 
)(x , then any SPRT for testing 
0 against 
) (0 1  has non -
decreasing power function.  
 
For the SPRT with error probabilities 
 and
 , the SPRT boundaries are given approximately by 
/) 1(A
 and 
) 1/(B .  The operating characteristics of the SPRT are given by 
) /()1 (),,,,()( )( )(
1 0  h h hB A A O  
 where 
)(h is the non -trivial solution to the equation 
1 );( )),(/);(()(
2 1 dxxf xf xfh 
.   
 
The formula 
);(/] log)( log)]( 1[[();(     zEB OA O NE   provides the average sample number 
for an arbitrary 
 .  The sample size distribution is very highly skewed, 
2)]([)( NE N Var .  Thus 
we will consider a truncated test with maximum sample size of 
0N  and simulate to obtain the 
operating characteristics of the test.  
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
 Derivation of the SPRT for Uncensored Exponential Survival Times  
 
For example, we wish to construct a sequential test for the composite null hypothesis that the rate 
of treatment -related m ortality (TRM) at 100 days is less than or equal to 30% versus the 
alternative hypothesis that it is greater than or equal to 50%.  For the derivation of the 
uncensored SPRT, we will require that the type I error of the test be less than 5%, and that the 
test provide 80% power to reject the null hypothesis under a specified alternative that the true 
rate is 50%.  A maximum sample size of 50 patients will be permitted.  
 
Let us assume that the survival times, 
nT TT ,...,,2 1 , are completely observe d (uncensored) and are 
i.i.d. with exponential density function 
Te Tf),( .  These assumptions will be relaxed to 
incompletely observed data subsequently.  In the exponential parameterization, a 100 -day 
survival rate of 70% translates into a mean survival of 0.768 years (
0 1.303), and 50% 
translates into a mean survival of 0.395 years (
1 2.532).  
 
The SPRT is derived with reference to a simple null and alternative hypothesis, in this case, 
o H:0
 1.303 versus
1 1: H  = 2.532.  However, since the log -likelihood ratio for the 
exponential, 
    n
in
in
ii i i T n xf xf ) ()) log() (log( ),( log);( log0 1 0 1 0 1    , is a 
monotone function of 
n
iiT , the power of the test is non -decreasing in 
 .  Thus the SPRT is a 
one-sided level .05 test of a composite null (
303.1 :0o H ) versus a composite alternative (
303.1 :1o H
), with power of 
80. 1  at the selected alternative 
1 2.532.  
 
The SPRT can be represented graphically.  The continuation region is bounded by two parallel 
lines with common slope 
  ) /() log (log1 0 1 0  0.541, and intercepts 
) /( log1 0A -2.256 
and 
) /( log1 0B 1.270, for the lower and upper bounds, respectively.  As each individual unit 
is put on trial and observed to fail, the cumulative sum of failure times,
n
iiT , is recomputed, and 
plotted against the current sample size, 
n .  When this graph crosses the lower boundary, the null 
hypothesis is rejected.  
 
The maximum sample size of 50 patients requires that the SPRT be truncated.  We choose t o 
truncate the SPRT by declaring that if the test has failed to terminate after 50 patients, that the 
null hypothesis will be accepted.  Since the probability that the untruncated SPRT would reject 
the null at a sample size of 50 is negligible, it makes li ttle difference how the final boundary 
value is selected, and this rule is chosen for simplicity.   
 
Derivation of a Modified SPRT for Censored Exponential Data  
 
The assumption of uncensored exponential survival times is flawed.  However, we consider it 
reasonable to assume the hazard for TRM is constant over the first 100 days post -transplant, and 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
 we will restrict our attention to this time interval.  Furthermore, it is not practical to conduct a 
clinical study by putting each individual on trial, and wait ing until that individual is observed to 
fail.  We relax our assumptions as follows.  Firstly, each individual’s time on study will be 
computed as time from transplant to failure, or to the 100 day time point, whichever comes first.  
Secondly, we will put individuals on trial as soon as they become available, without waiting for 
the previous individual to fail.  
 
Let us consider the impact of relaxing these assumptions one at a time.  In a fixed sample size 
trial with uncensored exponential failure times, me an survival time is estimated by the sample 
mean of the failure times, or total time on study divided by the number of individuals enrolled.  
When censoring is introduced, the estimate becomes the total time on study divided by the 
number of observed (non -censored) failures.  This suggests that in an exponential SPRT test 
modified to incorporate censoring, we replace the observed failure times, 
nT TT ,...,,2 1 , with 
censored failures times, 
nx xx ,...,,2 1 , and the current sample size,  
n, with the number of observed 
failures, 
d .   
 
Now we relax the second assumption, and put individuals on trial as soon as they become 
available, without waiting for the previous individual to fail.  Assum e that three years are 
required for accrual of 50 patients to the study, and that the final analysis takes place 100 days 
after the last patient is entered.  Putting all of this together, we propose a modified truncated 
SPRT, where at any interim time poin t, 
s, ranging from 0 to 3 years 100 days, the sum of 
observed time on study, 
n
iisX)( is plotted against the number of observed failures, 
)(sd .  In 
practice, monitoring will be scheduled month ly after the start of enrollment to the study.  A 
further modification to the SPRT was to only use the lower boundary for stopping since the 
primary focus of the monitoring is to protect against unacceptable 100 -day TRM rates.  
 
Operating Characteristics of  the Modified SPRT Test for Censored Exponential Data  
 
Recall that the uncensored SPRT targeted a drop in survival at Day 100 from 70% to 50%, with 
type I and II errors of 5% and 20%.  Since only the lower boundary is used for monitoring, the 
continuation region of the test was bounded below by a line with a s lope of 0.541 and intercept 
of –2.256.  The effect of truncation is to reduce the power of the test.  In order to compensate for 
this, we raise the lower boundary to make it easier to cross.  Under the further assumption of 
uniform accrual over a three yea r period, and monthly interim analyses over the course of the 
study, the operating characteristics of the modified SPRT were obtained from a simulation study.  
These simulation show that an intercept of –1.741, corresponding to setting parameters 
  and 

to 10% and 15%, result in empirical type I and II error rates of  about 5% and 20%.   
 
  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
 Table E -1   Operating Characteristics of Sequential Testing Procedures from a Simulation 
Study with 100,000 Replications  
 
Treatment -Related Mortality (TRM)  
True 100 -Day Rate  30% 35% 40% 45% 50% 
Probability Reject Null  0.07 0.20 0.41 0.66 0.86 
Mean Month Stopped  34.5 32.3 28.5 23.5 18.5 
Mean # Endpoints in 100 Days  13.8 15.0 15.1 14.0 12.1 
Mean # Patients Enrolled  48 45 40 33 26 
While the motivation for this testing procedure is largely heuristic rather than theoretical, the 
simulation results validate the approach.  When the true rate of TRM on or before Day 100 was 
30%, the test crossed the lower boundary in 7119 of 100,000 replications, for an estimated type I 
error rate of 7%.  When the true rate of TRM on or before Day 100 was 50%, the test failed to 
cross the boundary in 14226 of 100,000 replications, for an estimated type II error rate of 14%.   
And on average, the boundary will be crossed at 18.5 months, when 26 patients will be enrolled 
to the study.  
 
It is interesting to note that the SPRT derived above for exponential failure times with censoring 
at 100 days, has operating characteristics wh ich are similar to those of a more traditional SPRT, 
derived for binomial variates with success probability equal to the 100 day failure rate.  Using 
time to failure rather than a simple binary indicator of failure, leads to little improvement in 
power whe n failure times are censored relatively soon after entry on study.  We speculate that if 
the constant hazard rate over the first 100 days were high, the exponential test would reject faster 
than the binomial test, but have not conducted simulation studies to demonstrate this.  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
E-1 APPENDIX E  
 
SUGGESTED PREDNISONE TAPER FOR  
RESPONDING PATIENTS  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
  
APPENDIX E  
 
SUGGESTED PREDNISONE TAPER FOR RESPONDING PATIENTS  
 
 
Days  Dose  
Minimum of 3 days  
 2mg/kg/day  
Minimum  of 7 days  
 1mg/kg/day  
Taper weekly 
thereafter at the 
following intervals  Week 2  0.5 mg/kg/day once daily  
 
Week 3  0.25 mg/kg/day once daily  
 
Week 4  0.2 mg/kg/day once daily  
 
Week 5  0.1 mg/kg/day once daily  
 
Week 6  0.1 mg/kg/day every other day  
 
Week 7  Discontinue  
 
 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 2.0 dated July 7 , 2017  
 
 
F-1 APPENDIX F 
 
REFERENCES  
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 1. 3 dated April 19 , 2017  
 
 
 
 APPENDIX F 
 
REFERENCES  
 
  
1. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft -versus -host disease: a bench -to-
bedside update. Blood 2014;124:363 -73. 
2. Ziakas PD, Zervou FN, Zacharioudakis IM, Mylonakis E. Graft -versus -host disease 
prophylaxis after transplantation: a network meta -analysis. PloS one 2014;9:e114735.  
3. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe a cute graft -versus -
host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features 
and outcome. Blood 1990;75:1024 -30. 
4. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment 
trials. Blood 2010;115 :5412 -7. 
5. MacMillan ML, DeFor TE, Weisdorf DJ. What predicts high risk acute graft -versus -host 
disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk 
score. British journal of haematology 2012;157:732 -41. 
6. MacMilla n ML, Robin M, Harris AC, et al. A Refined Risk Score for Acute Graft -versus -
Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant -Related 
Mortality. Biology of blood and marrow transplantation : journal of the American Society f or 
Blood and Marrow Transplantation 2015.  
7. Srinivasan R, Daniels J, Fusaro V, et al. Accurate diagnosis of acute graft -versus -host 
disease using serum proteomic pattern analysis. Experimental hematology 2006;34:796 -801. 
8. Wang H, Clouthier SG, Galchev V , et al. Intact -protein -based high -resolution three -
dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell 
Proteomics 2005;4:618 -25. 
9. Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft -versus -host 
disease based on biomarkers: a multicentre study. Lancet Haematology 2015;2:e21 –e9. 
10. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or 
pentostatin plus corticosteroids for acute graft -versus -host disease: a randomi zed phase 2 trial 
from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009;114:511 -7. 
11. Bolanos -Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of 
steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: B MT CTN 
0802. Blood 2014;124:3221 -7; quiz 335.  
12. Pidala J, Tomblyn M, Nishihori T, et al. Sirolimus demonstrates activity in the primary 
therapy of acute graft -versus -host disease without systemic glucocorticoids. Haematologica 
2011;96:1351 -6. 
13. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network 
toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem 
cell transplantation. Biology of blood and marrow transplantation : journal of the Amer ican 
Society for Blood and Marrow Transplantation 2005;11:571 -5. 
14. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration 
after allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow 
transplantation : j ournal of the American Society for Blood and Marrow Transplantation 
2006;12:552 -9. 
Blood and Marrow Transplant Clinical Trials Network  Sirolimus vs . Prednisone – Protocol 1501  
Version 1. 3 dated April 19 , 2017  
 
 
 
 15. Mielcarek M, Furlong T, Storer BE, et al. Effectiveness and safety of lower dose 
prednisone for initial treatment of acute graft -versus -host disease: a randomized contro lled trial. 
Haematologica 2015;100:842 -8. 
16. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer 
patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634 -46. 
17. McQuellon RP, Russell GB, Cella DF, et al. Quality of lif e measurement in bone marrow 
transplantation: development of the Functional Assessment of Cancer Therapy -Bone Marrow 
Transplant (FACT -BMT) scale. Bone Marrow Transplant 1997;19:357 -68. 
18. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36 -Item Short -Form He alth Survey 
(SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health 
constructs. Med Care 1993;31:247 -63. 
19. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality 
of Life Invento ry version 4.0 generic core scales in healthy and patient populations. Med Care 
2001;39:800 -12. 
20. Lawitschka A, Guclu ED, Varni JW, et al. Health -related quality of life in pediatric 
patients after allogeneic SCT: development of the PedsQL Stem Cell Tran splant module and 
results of a pilot study. Bone Marrow Transplant 2014;49:1093 -7. 
21. Harris AC, Young R, Devine S, et al. International, Multicenter Standardization of Acute 
Graft -versus -Host Disease Clinical Data Collection: A Report from the Mount Sina i Acute 
GVHD International Consortium. Biology of Blood and Marrow Transplantation 2016;22:4 - 10. 
22. Jagasia MH, Hildegard TG, Arora M, et al. National Institutes of Health Consensus 
Development Project on Criteria for Clinical Trials in Chronic Graft -versus-Host Disease: I. The 
2014 Diagnosis and Staging Working Group Report. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation 
2015;21:389 -401 
 
 Hartwell MJ, Özbek U, Holler E, et al. An ear ly biomarker algorithm predicts lethal graft -
versus -host disease and survival. JCI Insight. 2017 Feb 9;2(3):e89798. doi: 
10.1172/jci.insight.89798.  
 
Major -Monfried  H, Özbek U , Renteria AS. Biomarkers predict graft-vs-host disease outcomes 
better than clinical response after one week of treatment . Blood 2016 128:510 (abstract).  
 
 
 
 